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ORAL BISOPROLOL IMPROVES SURGICAL  
FIELD IN FESS 
ABSTRACT 
Background:  
The success of functional endoscopic sinus surgery (FESS) depends on 
visual clarity of the surgical field, through the endoscope. The objective of this 
double-blind, randomized, controlled study was to determine if a pre-operative 
dose of Bisoprolol (2.5 mg) would reduce the bleeding during FESS and improve 
the visualization of the operative field. 
Materials and Methods: 
Sixty American Society of Anesthesiologists I or II patients, scheduled for 
FESS were randomized to receive either a Placebo (Group A) or 2.5 mg of 
Bisoprolol (Group B) 90 min prior to the surgery. All the patients received 
standard anesthesia and monitoring. The aim was to maintain the mean arterial 
pressure (MAP) of 60-70 mmHg, by titrating dose of  Sevflurane and Fentanyl. 
The concentration of  Sevoflurane used was recorded every 10 min. At the end of 
the surgery, the volume of blood loss was measured and the surgeon was asked to 
grade the operative field as per the Fromme-Boezaart Scale. 
 
 
Result:  
The blood loss was significantly (P < 0.0001) more in the Control group       
(97 ± 16.75  ml) as compared with that in the Bisoprolol group ( 58.3  ± 13.9 ml). 
The surgical field was graded better in those who received Bisoprolol as compared 
with those in the Control group ( P − 0.0001). The volume percent of  Sevoflurane 
and the dose of  Fentanyl used was significantly lower in those who received 
Bisoprolol. During the operative period, the MAPs were 92.87 ± 6.39 (Group A) 
and 78.25 ± 3.5 mmHg (Group B) and the heart rate was 94.75 ± 3.14/min (Group 
A) and 67.97 ± 1.84/min (Group B). These differences were statistically significant 
(P < 0.001). 
Conclusion:  
This clinical trial has demonstrated that administration of a single pre-
operative dose of bisoprolol (2.5 mg) can significantly reduce the blood loss during 
FESS and improve the visualization of the operating field. 
Keywords:  
Beta-blocker, bisoprolol, blood loss, functional endoscopic sinus surgery, 
surgical field 
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INTRODUCTION 
One of the mainstay of surgical treatments of sinusitis and nasal polyps is 
Functional Endoscopic Sinus Surgery. This includes bacterial, fungal, recurrent 
acute or chronic sinus problems. Ample researches have supported the record of 
safety and success of FESS. Advanced imaging techniques, better and  
increased understanding of the anatomy and the pathophysiology of the disease 
processes like chronic sinusitis, and image-guided surgery have allowed 
surgeons to perform more complex procedures with increased safety and 
reduced complications. 
 FESS is a relatively recent and advanced surgical procedure which uses 
nasal endoscopes through the nostrils to visualize the inner aspect and to avoid 
cutting the skin. Its introduction associated with enhanced illumination and 
visualization has dramatically improved surgical dissection. FESS came into 
existence through the pioneering work done by Dr.Messenklinger and his 
assistants in 1960 to 1970’s. 
 Remarkable short- and long-term results have been reported extensively 
in the literature. A report by Senior et al says that symptoms improved in 66 of 
72 (91.6%) patients following functional endoscopic sinus surgery, with a mean 
follow-up time of  7.8 years. In addition to the relief of symptoms, endoscopic 
sinus surgery also significantly influences quality of life. Damm et al reported 
an improvement in quality of life for 85% of the chronic sinusitis patient 
population, with a mean follow-up time of 31.7 months. 
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 But the very success of the use of endoscope for sinus surgeries depends 
on the visual clarity of the operating field. The sinonasal mucosa is very 
vascular and poor visualization due to excessive bleeding has been blamed for 
complications associated with this procedure. There is general agreement that 
bleeding can be reduced by maintaining a low blood pressure during the 
surgery. This can be achieved using high concentrations of anesthetic agents or 
administration of vasodilators like sodium nitroprusside. 
 Controlled hypotension is a technique used to limit intraoperative blood 
loss to provide the best possible field for surgery. Benefits of controlled 
hypotension for FESS include reduction in blood loss with improved quality of 
surgical field. Various agents e.g., magnesium sulphate,vasodilators (sodium 
nitroprusside) nitroglycerine, high doses of potent inhaled anesthetics, and beta 
adrenergic antagonist  have been used to achieve controlled hypotension. Some 
disadvantages have been reported of these techniques including delayed 
recovery from inhaled anesthetics, resistance to vasodilators, tachyphylaxis, and 
cyanide toxicity for nitroprusside. 
 However, these pharmacological techniques are associated with 
tachycardia which, apart from being an undesirable side effect, can increase the 
venous oozing and therefore obscure the surgical field. β-adrenergic receptor 
antagonist such as labetalol, metoprolol and esmolol have been shown to be 
useful in lowering the blood pressure and provide a relatively bloodless field for 
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surgery, but because of their short duration of action, this benefit does not last 
throughout the surgery 
The present work was designed to compare the efficacy of Bisoprolol as a 
hypotensive agent in FESS with attention on the amount of blood loss, quality 
of the surgical field and anesthetic requirements with Placebo. 
Indications for Endoscopic Sinus Surgery 
Endoscopic sinus surgery is most commonly performed for inflammatory 
and infectious sinus disease. The most common indications for endoscopic sinus 
surgery are as follows:  
• Chronic sinusitis refractory to medical treatment 
• Nasal polyposis 
• Antrochoanal polyps 
• Sinus mucoceles 
• Excision of selected tumors 
• Cerebrospinal fluid (CSF) leak closure 
• Orbital decompression (eg, Graves ophthalmopathy) 
• Optic nerve decompression 
• Dacryocystorhinostomy (DCR) 
• Choanal atresia repair 
• Foreign body removal 
• Epistaxis control 
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AIMS AND OBJECTIVES 
 
1. To compare the efficacy of BISOPROLOL 2.5 mg orally in  reducing the 
bleeding during Functional Endoscopic Sinus Surgery and improving  the 
visualization of the operating field with PLACEBO. 
 
2. To compare the requirements of  anesthetics like Sevoflurane and 
Fentanyl during the procedure with BISOPROLOL and PLACEBO. 
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HISTORY 
 
Rhinology and sinus surgery have undergone a tremendous expansion 
since the discourses of  Messerklinger and Wigand in the late 1970s. 
 In 1901, Hirschmann was the first to attempt endoscopic 
examination of the sinonasal cavity using a modified cystoscope 
(Hirschmann, 1903). This was followed by Reichert, who performed 
the first endonasal sinus surgery with a 7-mm endoscope for closure 
of oroantral fistulas (Imhofer, 1910). In 1925, Maltz promoted the 
use of nasal endoscopes for diagnostic evaluation of the sinonasal 
cavity and coined the term sinuscopy, describing methods for 
visualizing the maxillary sinus by placing endoscopes through the 
canine fossa or inferior meatus (Maltz, 1925). However, inadequate 
illumination and difficulties with depth of field discouraged their 
widespread use until the 1960s, when Professor H. H. Hopkins’ 
recently developed rod optic system was manufactured, dramatically 
improving resolution, widening the field of vision, and increasing 
light intensity sixfold over prior endoscopes. It was Messerklinger 
who was the first to use these nasal endoscopes to systematically 
analyze the anatomy of the lateral nasal wall and the mucociliary 
patterns of the paranasal sinuses (Messerklinger, 1978). Through his 
studies and detailed endoscopic photodocumentation, he determined 
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that widespread infection of the sinonasal cavities often appeared to 
originate from pathology within the narrow recesses of the lateral 
nasal wall. This led to the concept that minor endoscopic surgical 
removal of disease within this region and enlargement of natural 
sinus ostia should result in spontaneous resolution of pathology 
within the adjoining sinuses. Messerklinger compiled all of his 
endoscopic observations and published his findings in 1978. 
However, Messerklinger’s work did not include the potential 
endoscopic surgical resolution of these diagnostic observations and 
therefore did not receive widespread recognition. 
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Later, in 1984, Kennedy, who had also previously performed 
animal studies on mucociliary clearance and microscopic endonasal 
ethmoidectomies, had the opportunity to witness a video 
demonstration of Messerklinger’s work on cadaveric mucociliary 
transport while attending a conference in Dubrovnik.  
 
The presentation prompted him to visit Stammberger and 
Messerklinger in Graz, where he had the opportunity to observe 
Messerklinger’s endoscopic diagnostic and operative techniques 
firsthand. Visits also to Wigand in Erlangen and Draf in Fulda 
provided further experience with endoscopic surgical approaches 
and enabled him to begin incorporating these endoscopic techniques 
into his own operative procedures and to begin working with Karl 
Storz to develop a set of instruments for endoscopic sinus surgery. 
Zinreich, working with Kennedy at Hopkins, developed computed 
tomography (CT) parameters for sinus imaging and demonstrated the 
superiority of this modality over the previously available plain films 
and polytomograms for imaging sinonasal disease, particularly 
within the ethmoid sinus and ostiomeatal complex. 
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They termed these new endoscopically guided diagnostic 
evaluations, and more focused therapeutic and surgical techniques, 
“Functional Endoscopic Sinus Surgery.” In 1985, the first 
instructional course on endoscopic sinus surgery was organized at 
Hopkins and the use of endoscopic sinus surgery has only grown 
more widespread with the passage of time. 
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SURGICAL  ANATOMY OF NOSE AND PARANASAL SINUSES 
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HISTORY 
The literary evidence of paranasal sinus way back to Galen (AD 160-
201). He described the ‘’porosity” of bone in the head. Leonardo Da vinci 
illustrated the maxillary antrum and the fronal sinus from his classical sections 
of head. He also recognised these as individual functional cavities. Maxillary 
sinus has been referred as a cavity bone that supports the cheek. First detailed 
description of maxillary antrum was given by Highmore in 1651. Since then 
maxillary antrum is referred as “Antrum of Highmore”. 
But only in 19th century paranasal sinuses were described anatomically 
and pathologically in a detailed manner, by Zuckerkandl who also published 
that all these descriptions are more valuable that it can be applied to the patients 
problem directly. 
        X-ray invention did not contribute much to the knowledge of sinus 
anatomy. But in mid 1970s, availability of CT clearly showed the relationship 
of ethmoids with the largest sinus.Since 100 years this knowledge has been 
developed and applied. 
        Drawings by  Onodi, Grenwald and Zuckerkandl are compared with 
CT which demonstrated the accurate knowledge of these pioneers. At the upper 
airway entrance four pairs of air filled cavities forms a complete unit. During 8th 
week of embryogenesis, paranasal sinuses develops from the lateral nasal wall. 
Pneumatisation of paranasal sinuses continue till adulthood. Each 
paranasal sinus are named after the bone in the skull where it is located. While 
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development, involvement of adjacent bones is seen during pneumatisaion, as 
with the case of ethmoid sinus which is developed into frontal, maxillary or 
sphenoid, and extension of maxillary sinus in zygomatic bone. The lining of 
paranasal sinus is by pseudostratified epithelium which also lines the respiratory 
tract.  
It is composed of, 
• Ciliary column 
• Nonciliary column 
• Goblet , mucous and basal cells 
When the mucosa is attached to bone, it is referred as mucoperiosteum. 
The mucoperiosteum of sinuses are in continuity with the nasal cavity via the 
ostia and sinuses. An ostium is a opening via which sinuses drains into airway, 
either into nasal cavity directly or by complex structures indirectly. 
          When compared to older surgical for paranasal sinus the new concept of 
FESS acknowledged that sinus ostium and its lining mucosa has an essential 
role in inflammatory process involving paranasal sinus. So, the diseases of 
mucosa and its symptoms can be reversible by obtaining proper drainage via the 
ostium. 
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NASAL CAVITY: 
 
           The first cavity encountered during FESS is the nasal cavity. Paranasal 
sinus opens into the posterosuperior and lateral walls of nasal cavity. Through 
choanna, nasopharynx  is reached by the posteroinferior walls. 
            In the beginning of FESS surgery, identifying the relationship of choana 
with the posterior nasal sepum and the Eustachian tube is very important. When 
nasal airway is obstructed in the inferomedial part by the polyps ,nasal cavity 
patency must be re-established first. For visualising the choana and providing 
route for the drainage of blood into the nasopharynx. Conchae or turbinates 
forms the ridges in the lateral wall of nasal cavity. Embryologically the inferior 
turbinate is derived from maxilloturbinate. It is inserted on the maxilla 
anteriorly and on the palatine bone posteriorly. 
Mourett in1922 described conchal lamina, from which ethmoid turbinates 
develops(superior and middle). It is a bony plate which is attached between the 
cribriform and the roof of ethmoid. The turbinates subdivides the nasal cavity in 
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the lateral part into meati which are four in number. Inferior meatus lies 
between the lateral wall and inferior turbinate and the medial wall and maxillary 
sinus. Its distal opening leads to nasolacrimal duct, covered by Hasner’s valve. 
Space between lateral and middle turbinate by middle meatus. Functionally it is 
known as osteomeatal complex. It contains pathways of drainage for anterior 
ethmoid, frontal and maxillary sinus. Chronic rhinosinusitis is most commonly 
involved in the area of middle meatus. 
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In the middle meatus, the structures seen from anterior side to posterior side are; 
• Cells of agar nasi 
• Uncinate process 
• Hiatus semmilunaris 
• Ethmoid bulla 
• Sinus lateralis 
• Posterior fontanelle 
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SUPERIOR MEATUS: 
 
            It is the lateral space between middle and superior turbinates. Post 
ethmoid cells are drained by it. Area which drains the post ethmoid cells is the 
supreme meaus which is the space above the superior turninate.  
          Nasal cavity is divided as superior part by olfactory cleft in the anterior 
space, posteriorly by sphenoethmoid recess. The location of olfactory cleft 
under olfactory fossa between the nasal septum and the insertion of middle 
turbinate. Just inferior to cribriform plate is its location. Depending on how low 
the cribriform plate is located in relation with the roof of ethoid,keros classified 
olfactory fossa into 3 types. 
 
Keros classification: 
 
 Type 1 is 1 – 3 mm deep in relationship to the roof of ethmoids and 
it corresponds to an olfactory fossa. 
 Type 2 is 4 – 7 mm deep. 
 Type 3 refers to a depth of 8 mm and above. 
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To avoid breaking into the skull base anteriorly, relationship between 
fovea ethmoidalis, cribriform plate and insertion of superior and middle 
turbinates are important. 
       Especially in the least resistant zone, where anterior ethmoid lies between 
ethmoid roof and conchal lamina. The roof of nasal cavity is very inferior in the 
posterior part of olfactory cleft, where the sphenoethmoid recess curves in 
between the posterosuperior septum and the tail of superior turbinate above 
choana. Posterior ethmoids and ethmoid sinus are drained by this recess through 
supreme and superior meati. This area is also referred functionally as 
“posterior” osteomeatal complex, in par with “anterior” osteomeatal complex of 
middle meatus. 
            Sphenoid recess constitutes an important surgical landmark which is the 
tail of superior turbinate, since it is pointed medially to the sphenoid sinus. 
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MAXILLARY SINUS AND UNCINATE PROCESS: 
 
 
 
                In endonasal sinus surgeries, Uncinate process is the important 
landmark which is located in the lateral wall of the nose. Though it is derived 
from the 1st ethmoturbinal and considered as a part of ethmoid labrynth, 
typically it is discussed with maxillary sinus due to its close relationship with its 
ostium. 
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Uncinate process is a bony structure which is crescent in shape.It is 
projected posteroinferior to anterosuperior and runs across the lateral wall and 
nose where it is attached to the maxilla, skull bone and lacrimal bone.It is not 
attached to any of the bony part anteroinferiorly.It is attached to the inferior 
turbinate (ethmoid process) posteriorly. Anteriorly  it forms the boundary for 
osteomeatal complex.It hides hiatus semilunaris endoscopically which is 
represented as a space between ethmoid bullae and uncinate.Polypoid disease 
and maxillary sinus hypoplasia displaces the uncinate process medially and 
laterally. 
 In most of the endoscopic sinus surgeries removal of the uncinate process 
is the first step. During surgery, the insertion of uncinate process anteriorly 
should be considered to avoid injury to the medial side and the orbital wall. In 
this step the ostium and the maxillary sinus is revealed. The orbital floor level is 
identified by the superior and the ostium of maxillary sinus. The most constant 
and the largest of the paranasal sinuses is the maxillary sinus. It is the first one 
to be developed in utero. It undergoes rapid growth at two phases of life. One 
upto 3 years of life and another between 7 and 18 years.The facial surface of 
maxilla corresponds to the anterior wall of the maxillary sinus. 
 A bony wall present posteriorly seperates it medially from 
pterygomaxillary fossa and laterally from infratemporal fossa. Medial wall is 
formed by mucosa of the middle meatus,sinus mucosa and connective tissue. 
The posterior fontanalle can also have an accessory ostium which opens into the 
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maxillary sinus. During FESS surgery if uncinectomy is incomplete this could 
be mistaken for the natural ostium. The location of anterior fontanelle is 
between the inferior turbinate inferiorly and uncinate superiorly. Hard palate 
and the alveolar process in the maxillary bone forms the floor of the sinus. 
  
 In children it lies in the same level to the nose and in adults it is located   
5 – 10 mm beneath the floor of the nose. In maxillary sinus floor of the orbit 
forms the roof and it houses a bony canal for the 2nd branch of Trigeminal 
nerve. The prescence of Haller cells ( infraorbital ethmoid cells ) are the 
anatomical variation most commonly found. The Ethmoid cells that are 
pneumatised projects along the orbital floor and most commonly arises from 
anterior ethmoids. In some cases it can be involved in polypoidal diseases and 
in others  and the patency and the maxillary sinus infundibulum can be 
compromised. 
 Clear identification of the floor of orbit and the posterior wall of the 
maxillary sinus can be done by removing infraorbital ethmoids. Often it is an 
important and  most reliable surgical landmark in case of advanced diseases and 
distorted anatomy of middle meatus. 
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ETHMOID LABRYNTH 
 
 
  
Ethmoid sinus is located between the nasal wall laterally and the orbital 
wall medially and lateral to olfactory cleft. It is compartmentalised. 
Pneumatization occurs with only few cells at birth and it goes beyond 15 cells in 
adulthood. 
 The fromtal bone extends posteriorly to cover the roof of ethmoid 
sinus,forming the fovea.Along the roof of ethmoid sinus runs the anterior and 
posterior branches of Internal Carotid artery,from lateral to medial side.Due to 
the cone like structure of the orbit the width increases feom anterior to 
posterior.Complex anatomy due to honeycomb appearance of air cells with 
blind alleys and intricate passageways made ethmoid sinus to be referred as 
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ethmoid labrynth.This complex anatomy is simplified by rhinologists by 
describing the sinus as 5 paralell lamelles oriented obliquely. 
 These lamelles are easily recognised intraoperatively since their 
consistency.The first anterior lamella represents the  basal lamella of the first 
ethmoturbinal embryologically.Most of this corresponds to the uncinated 
process. The second lamella is called the “ethmoid bulla”. Zuckerkandl reffered 
it as bulla ethmoidalis and it is found to be the largest and most consistent 
anterior ethmoidal cell. It is round in shape and it extends from laminae 
papyracea on the lateral side and bulges into the middle meatus medially. The 
third lamella is the most important which is the basal lamellae and the middle 
turbinate that anatomically seperates the anterior and posterior ethmoidal cells 
and also creates a septa which dictates the drainage of the anterior ethmoidal 
cells into the middle meatus and the posterior ethmoidal cells into the superior 
meati. Thus it represents as the posterior limit while doing anterior 
ethmoidectomy. The 4th and the 5th lamellae are the basal lamellae of the 
superior and supreme turbinates respectively. 
 In addition to the bony lamellae there are particular groups of ethmoidal 
cells, recognising of them helps in understanding the pathophysiology of the 
disease process and helps in doing a near complete ethmoid surgery that is 
associated with least number of complications.With endoscopy agger nasi cells 
which are the most important anterior ethmoidal cell are visualised prominently 
anterior to the middle turbinate.Agger meaning eminence or mound in Latin and 
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agger nasi is referred to the first ethmoturbinal which is a pneumatised superior 
remnant. 
 It persists as mound superior and anterior to the middle turbinate. 
Inferiorly pneumatisation extends to involve the uncinated process which is 
very rare. Pneumatization of agger nasi significantly has impact on the frontal 
recess pateny and the insertion of the uncinated process. Frontal recess is 
accessed surgically with accurately identifying the agger nasi. Sometimes 
middle turbinate is pneumatised forming circular bullosa. Pneumatization 
originates uasually from tha agger nasi or the frontal recess. 
 The concha bullosa usually does not require surgery since it is a normal 
variant.But when the pneumatisation is extensive narrowing of the osteomeatal 
complex may occur leading to sinus diseases.Conchal cells which invades the 
middle turbinate anteriorly are ethmoidal cells but lamellar cells arises due to 
pneumatisation of the middle turbinate from superior meatus. These conchal 
cells are described by Grunwald. 
 The supraorbital ethmoidal cells also known as suprabulbar cells are 
anterior ethmoidal cells that extends upon the orbit by orbital plate 
pneumatisation.They arose behind the frontal recess.They compromise the 
drainage of the frontal sinus posteriorly like agger nasi cells in the anterior 
part.Inexperienced surgeons usually mistakes the supraorbital cells for the 
frontal sinus.With transillumination using a telescope, these can be 
differentiated. 
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 In frontal sinus the inner canthal area is illuminated.Yet another 
important group of cells are the sphenoethmoid cells. They are referred to as 
Odoni cells, since  Adoff  Odoni studied the relation between ethmoid and optic 
nerve. The extent of posterior ethmoidal cells are up to the superior and lateral 
part of sphenoid sinus and the pneumatisation can extend up to the clinoid 
process. The sphenoethmoid cell has intimate relationship with the optic nerve 
in the lateral wall. 
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THE SPHENOID SINUS: 
 
 
              
 The location of sphenoid sinus is at the junction of middle and anterior 
cerebral fossa which is located at the base of the skull. While fetal development 
it starts its growth in the 3rd and 4th month. It starts as an  invagination of 
mucosa of the nasal cavity into the cartilaginous part of the nasal capsule. It is 
present as a pit in spheno ethmoidal recess a birth upto 3 years. At three years o 
age pneumatisation starts, at seven years of age extension into the sella turcica 
occurs. At middle of the teens its final form is reached. First it is developed as 
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sinuses that are two in number which are asymmetrical. A bony septum 
separates both the sinuses. Since they are asymmetrical, bony septum is not 
exactly in midline and can be inserted posteriorly on the carotid canal, which is 
situated in the lateral wall of sphenoid. 
So great care is taken while removing the septum, rupture of carotid can 
happen on avulsion of the bone. The clinoid processes as the vomer which 
constitutes the posterior part in the nasal septum can be invaded when 
pneumatisation of sphenoid occurs. The drainage of sphenoid is into the spheno 
ethmoidal recess via a single ostium. The ostium is located at the base of 
columella which measures around 7 cm and situated at 30 degree angulation. 
The posterior and inferior end of superior turbinate is pointed medially and 
superiorly to the ostium. 
          This is the most important landmark to identify the ostium in endoscopic 
view. Distortion of the normal anatomy can occur during polypoid changes, 
then the location of ostium can be adjacent to the septum of nasal cavity in level 
with posterior part of the orbital floor through sinusotomy of the middle meatus. 
This location is approximately 10-12 mm to the superior arch of choana and 7 
cm of columella. The floor of sella turcica forms the superior wall. Sphenoid 
sinus is classified depending on the extent to which pneumatisation occurs. 
• Conchal-It is located below sella. It is a solid block of bone in which 
pneumatisation has not occurred. 
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• Presellar – when pneumatisation of sphenoid is upto the frontal plan of 
sella turcica. 
• Sellar – here extention of pneumatisation occurs upto and beyond the 
body of sphenoid. This is the most common type. 
 The prominences of optic canal and carotid canal is located in the 
sphenoid sinus in its lateral wall. 
          The medial most structure in cavernous sinus is the internal carotid artery 
which rests on the lateral part of sphenoid bone. Its prominence varies within 
the sphenoid sinus. It can be  simple local bulge to a serpigenously elevated 
which masks the full course of(posteroinferior to posterosuperior) the carotid 
artery within the sphenoid sinus. Dehiscence of bony margin should be looked 
for in the CT scan even when the disease is not advanced. The location of optic 
canal is present between superior, lateral and posterior walls of the sphenoid 
sinus at an angle poserosuperiorly. It crosses the carotid canal lateral to 
medially. In sphenoid when pneumatisation occurs blow and above the optic 
canal it results in opticocarotid recess. The location of infraoptic recess is 
between the carotid canal in the inferior portion and superiorly the optic nerve. 
Sometimes pneumatisaion of clinoid process occurs. 
In the lateral wall canals for 2 more nerves can be present. 
• Trigeminal nerve(2nd branch) passes superiorly through foramen 
rotandum. 
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•  Inferiorly the viridian nerve which passes through the pterygoid canal 
when the sphenoid sinus is extensively pneumatised these nerves are 
identified easily in a coronal CT scan which defines the both (superior 
and inferior) borders of entry into lateral recess. 
 
 
THE FRONTAL SINUS: 
 
 
          The frontal sinus is related intimately to the anterior ethmoid both 
embryologically and anatomically. The frontal sinus is developed from the 
anterior ethmoid cells which extends upwardly into the inferior part of the 
frontal bone in between the lateral tables.  
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           But according to Stammberger development of frontal sinus is from 
frontal recess which is embryologically the continuaion of groove present in 
between first and second ethmoturbinal. At birth, it is blind pouch which often 
cannot be distinguished from anterior ethmoid cells. Pneumatisation starts at 2 
years, significant in adolescence and gets completed in late teens. The  left and 
right frontal sinuses are asymmetrical and develops independently. Sometimes it 
is common to find one frontal sinus, or the frontal sinus may be aplastic, 
hypoplastic, or rarely aplastic bilaterally. The fontal sinus llies between the 
anterior thick and posterior thin tables of the frontal bone which separates the 
sinus from the posteriorly situated frontal lobe. It is described pyramidal in 
shape with the boundaries of a bony septum medially, intersinus cell formed by 
intersinus septum which is pneumatised sometimes, and the floor by the roof of 
the orbit. The pathway for the drainage of frontal sinus is in an hourglass shape 
which opens in the level of frontal recess. Narrowest point in the tract is known 
as ostium or the frontal infundibululm. It is located at the inferomedial aspect. 
The boundaries of frontal ostium are formed by, 
 Anteroinerior part is formed by roof of agger nasi,  posterior part is 
formed by roof of bulla ethmoidalis, lateral part by lamina papyracea and 
anteriorly by middle turbinate. Different groups of anterior ethmoid cells are 
related to rontal inundibulum. Others which originate from frontal recess are 
known as frontal infundibular cells. 
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Frontal cells are classified into  types by Bent and Kahn 
 Type I – When single air cell lies above agger nasi. 
 Type II – When group of cells are present above agger nasi and below the 
roof of the orbit. 
 Type III – when a single cell extends into frontal sinus from agger nasi. 
 Type IV – When a cell is present in isolation inside the frontal sinus 
which is noncontagious with agger nasi. 
           Frontal sinus infundibulum is the most difficult area to be accessible in 
FESS surgeries, due to their smaller diameter, anterior most locataion and 
orientation inside the frontal bone. Its anatomy related to the orbit, the bone of 
the skull and presence of various groups of cells makes the anatomy most 
difficult to understand during endoscopy. For a sae and successful visualisation 
the keys followed during FESS are opening of agger nasi cells, identification of 
posterior wall by palpating with probe. 
          Down fracturing the agger nasi and suprabulbar roof and carefully 
removing for better visualisation of the infundibulum.  Track of entry into 
frontal infundibulum is via the direction of a parallel line drawn to the lacrimal 
bone at its maximum convexity, behind the middle turbinate, starting at the 
maxillary sinus in the coronal plane.    
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Blood supply of the nose: 
I. External nose 
1). External carotid artery: 
 Facial artery – 
• Angular branch,  
• Alar branch, 
• Septal branch,  
  -   External nasal branch. 
2). Internal carotid artery: 
 Ophthalmic artery – 
• Dorsal nasal branch. 
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Fig. Blood supply to the external nose 
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II. Nasal septum 
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III. Lateral wall of nose and turbinates : 
 
 
 
 
 
Fig. Arterial network of  the lateral wall on nose 
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Fig.Blood supply to the lateral wall on nose 
 
Internal carotid: 
Ophthalmic artery  
• Anterior ethmoid artery to Anterior 1/3 of lateral wall and septum 
• Anterior lateral branch  
• External nasal branch 
• Anterior setal branch 
• Posterior ethmoid artery to superior concha  
External carotid: 
Maxillary artery -  
• Sphenopalatine artery.  
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Posterior lateral nasal branch to run along MT & IT 
Posterior septum branch 
• Facial artery -  
Superior labial artery to Nasal septal branch 
Lateral nasal branch  to Alar branch 
• Infraorbital artery 
• Descendig palatine artery to Greater palatine artery. 
  Superior alveolar artery 
Venous drainage 
• Roof  
• Ethmoidal vein to Ophthalmic vein 
• Posterior  
• Sphenopalatine vein  to pterygopalatine fossa  to pterygoid 
venous plexus 
• Anterior  
• Anterior facial vein  to External or Internal jugular vein 
 
Nerve supply of nose: 
 Nose is mainly supplied by the following : 
• General sensory fibers (CN V1,CN V2) 
• Parasympathetic fibers : secretomotor fibers 
• Sympathetic fibers : vasomotor fibers 
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HISTORY OF INDUCED HYPOTENSION 
Definition 
Controlled hypotension is defined as producing a predictable decrease in 
the blood pressure but at the same time limited by safety. It was taken from the 
very early studies done by ECKENHOFF and RICH in 1960’s.The lowest 
limit of blood pressure should not be determined before the start of the surgical 
procedure but rather should be provided till the desired level that is the 
bloodless field is achieved but within the safety limits without compromising 
the cerebral or the coronary blood flows. However  the safety limit has to be 
individualised. 
  In general, MAP as low as 50 mmHg or a 30% fall in MAP is considered 
safe for a ASA 1 subjects. However this might not be considered as a safe limit 
for a chronic hypertensive patient who will not tolerate a fall in MAP more than 
25%.Again this cannot be appropriate level for a patient with cerebrovascular 
disease as they cannot tolerate any sort of decrease in MAP. 
Evolution of  Induced hypotension. 
 It was during 1917, induced hypotension first introduced into practice so 
as to provide a bloodless field for neurosurgery. 
 In the year 1946, arteriotomy  as a technique to produce a bloodless field 
was introduced. 
37 
 
 Regional anesthesia had also been used in inducing hypotension to create 
a dry field. In 1948,high spinal anesthesia and in 1951 high epidural block were 
also used. 
 The method of inducing hypotension evolved further and the technique of 
ganglion blockade using pentamethonium, hexamethonium and trimethaphan 
were used during anesthesia. 
 Thereafter deepening the plane of anesthesia with the help of volatile 
inhalational agents was a favourite choice by many anesthesia practitioners. 
 For the first time in 1962,sodium nitroprusside was used to induce the 
hypotension during anesthesia. 
 Since then many drugs have evolved for the purpose of inducing 
hypotension .Nitroglycerine, calcium channel blockers, beta blockers, purine 
compounds and prostaglandin E1 have been used for it. 
PHYSIOLOGY : 
 Adequate knowledge and understanding of regulation of blood flow to the 
vital organs is obsolute necessary to produce induced hypotension for the 
optimal benefit of the patient. Controlled hypotension rarely produces any 
damage, nevertheless because blood flow to the vital organs are well maintained 
due to the wide range of autoregulation. 
 Blood flow to cerebral, myocardial and renal beds depends on the 
function of both MAP and auto regulation. Hence the concept of MAP is used 
in the practice of controlled hypotension rather than systolic blood pressure. It is 
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of at most importance to determine the weak link among these three vital organs 
that sets the minimal permissible pressure. So  the physiology of these three 
systems needs to be examined separately. 
Mechanisms of auto regulation: 
1. Myogenic  response – response of the vasculature to the altered tension 
detected in the smooth muscle. 
2. Passive response – this happens in an encapsulated organ in which 
increasing pressure dur to expansion of the organ compresses the thin 
walled vessels and leads to an increased vascular resistance. 
3. Metabolic response – changes in the blood pressure produces vasoactive 
substances. 
 The organs capable of autoregulating their blood flow are able to 
maintain the perfusion over a wide range of blood pressure changes. Only when 
the blood pressure reduces to a relatively low level they cannot maintain their 
perfusion. This is called critical blood pressure and it varies from organ to 
organ, vessel to vessel and probably from patient to patient. 
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CEREBRAL CIRCULATION 
  
 It is a common belief that it is the cerebral perfusion pressure  that is 
critical in deciding the lower limit of MAP. This is probably because even a 
minimal derangement in the perfusion pressure of the cerebral circulation 
produces an unacceptable postoperative dysfunction of  the organ. By the way 
of autoregulation, cerebral blood flow is normally maintained at 45 – 50 
ml/100gms/min. This is achieved through a MAP ranging from 50 -150 mmHg. 
 The absolute value of cerebral blood flow below which the cerebral 
ischemia occurs is nor clearly understood. But there are several studies 
reporting an estimate can be made. Sundt et al used xenon to measure the 
cerebral blood flow and he simultaneously recorded EEG during carotid 
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endarterectomy during anesthesia with volatile agents like Halothane and with 
normocapnia. 
 In that study they had found that there were no changes indicative of 
cerebral ischemia if cerebral blood flow was above 25 mls/100gms/min. 
Considering this as the critical flow limit, it is possible to estimate a critical 
cerebral perfusion pressure below which cerebral ischemia might occur. 
 Never the less, there are several factors that can modify the circulation 
under the control of anesthesiologist. 
1.PaCO2 
 Arterial PCO2 is the most important determinant of cerebral blood flow 
within the range of autoregulation.Cerebral blood flow increase by 1 ml/100 
gms/min for every 1 mmHg increase in the arterial PCO2 and vice versa. 
 This is relevant in the clinical situation as hypocapnia is a part of the 
induced hypotensive technique.The cerebral function could be compromised if 
both hypotension and the vasoconstrictive effects of the low PCO2 on cerebral 
vessels are combined. 
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2.PaO2 
 Changes in the arterial oxygen tension also affect the cerebral blood flow. 
The brain protects itself by vasoconstriction when exposed to very high oxygen 
tensions like in the hyperbaric range which can induce toxic effects on the 
cerebral circulation. 
 This is demonstrated by a reduction of cerebral blood flow by 1/5 th 
whenever there is an exposure to 100% oxygen. 
 On the other hand if arterial oxygen tension is decreased below the 
normal level, the cerebral blood flow increases due to vasodilatation. Though 
administering high concentration of oxygen during induced hypotension may 
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not be beneficial as far as the cerebral blood flow is concerned, it may be 
necessary to offset the effects of hypotension on the pulmonary gas exchange. 
 
3.Volatile agents : 
 The effect of volatile liquid agents is to attenuate the autoregulation in a 
dose dependant manner. This differs from agent to agent and is in the following 
order.Halothane  > Enflurane > Isoflurane. 
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4. Temperature  
 There is a linear relationship between temperature and cerebral blood 
flow .Hypothermia induces cerebral vasoconstriction whereas hyperthermia 
causes cerebral vasodilatation. For every degree celcius change in the body 
temperature cerebral blood flow changes by 5 – 7%. 
5.Vasodilators 
 Drugs like Sodiumnitroprusside and Nitroglycerine attenuate the 
autoregulation of cerebral blood flow same as the volatile liquid agents does. 
When overall cerebral blood flow is contrasted with the regional blood flow 
difficulty in interpretation occurs. This is because in the region of marginal 
blood flow factors such as hypoxia and local acidosis predominate, which may 
cause maximal dilatation of cerebral vessels in that area. 
 As there is a limitation of  the volume of blood that can be accommodated 
within the skull vault, events that can cause increase in the blood flow to the 
areas of perfusion may displace the blood flow to the areas of marginal 
perfusion. 
 Because of this unequality and uncertainity of regional blood flow 
distribution , a safety limit has to be determined as far as the MAP is concerned. 
It has been found in this way that it should be safe to lower the MAP to 50 
mmHg without any significant decrease in the cerebral blood flow. 
 In case of chronically hypertensive patients ,they have their cerebral 
autoregulation curve shifted to higher side on both the ends.For them the safest 
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lower limit of MAP can be calculated based on this curve shift.Even the 
elevated MAP of these patients are taken into account,they pose an increased 
risk.Therfore chronically hypertensive patients are relatively contraindicated for 
the induced hypotension technique. 
 
 Elevated position of the head during induced hypotension anesthesia can 
decrease the cerebral perfusion pressure further. For every 2.5 cm raise in the 
head position above the point of monitoring the cerebral perfusion pressure 
decreases by 2 mmHg. 
CORONARY CIRCULATION 
 The coronary blood flow depends on the aortic diastolic pressure and the 
coronary vascular resistance. The autoregulation of coronary blood flow is 
predominantly determined by the coronary vascular resistance that is made to 
meet the myocardial oxygen demand. 
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 Obviously hypotension decreases the coronary blood flow but however it 
simultaneously decreases the myocardial oxygen demand due to reduction in the 
after load and/or preload. Rollason et al in 1959 reported that there is a poor 
correlation between the lowest value of hypotension and the development oh 
ischemic changes in ECG during hypotensive anesthesia. 
 
 In patients with coronary artery disease,some area of myocardium are 
entirely dependant upon the pressure to have an adequate blood flow.Usage of 
vasodilators in these patients readily produces a steel phenomenon which 
compromises the blood flow to the ischemic areas further.Hence the technique 
of induced hypotension is accompanied by significant intraoperative risk of 
myocardial infarction in these patients. 
 In a study done by Rollason & Hough,in 1959,induced hypotension with 
the use of ganglion blocking agents,they had found that although 40% of cases 
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had evidence of transient myocardial ischemia ,none had ECG changes 
suggestive of myocardial ischemia. They observed that these changes occurred 
in elderly patients or patients with a history of  pre-existing chronic 
hypertension of their study group, when the systolic blood pressure fell below 
60 mmHg. They concluded that a MAP limit of atleast 80 mmHg should be 
maintained at all times in these patients whenever hypotensive anesthesia is 
contemplated.   
RENAL CIRCULATION 
 
Renal blood flow is regulated in two ways. 
 1.Extrinsic autoregulation 
  Autonomic response 
  Hormonal response 
 2.Intrinsic autoregulation 
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 In 1954,Miller, De Wardener and Venton showed that the renal blood 
flow autoregulation ranged over 80 -180 mmHg. This renal blood flow 
autoregulation gets attenuated during general anesthesia and even a slight 
reduction in blood pressure reduces the renal blood flow. This occurs when 
systolic blood pressure is 80 – 90 mmHg as observed by Larson et al in 1974. 
 Further drop in the arterial blood pressure decreases the renal blood flow 
to a point where the urine formation fails. When MAP is decreased below 75 
mmHg the GFR gets reduced. 
 Drugs like volatile agents and opioids used during hypotensive anesthesia 
stimulate the secretion of Anti Diuretic Hormone which results in oliguria. 
 Renal blood flow has also got a critical value as with cerebral circulation, 
below which acute renal failure occurs. Again the critical value differs from 
individual to individual and also depends on the pre-existing renal disease. 
Therefore during induced hypotension, if the reduction in renal blood flow is 
not below the critical value it is unlikely to have any serious kidney damage. As 
a matter of fact, it has been shown that the urine formation rapidly returns to 
normal as soon as the hypotensive anesthesia is terminated. 
HEPATIC CIRCULATION  
       Liver gets in maximum blood flow from portal vein (70%).Remaining 30% 
is by hepatic artery. The splanchnic circulation has got rich innervations by the 
sympathetic nervous system unlike the brain and kidney which are 
autoregulated, the liver is not autoregulated. Therefore any decrease in blood 
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pressure readily decreases the blood flow to liver. In addition to this, the 
splanchnic circulation which is highly innervated with sympathetic nervous 
system responds to any increase in paco2 or any decrease in Paco2 by a 
catecholamine response and causes decrease in liver blood flow. The decrease 
in hepatic blood flow by hypercarbia occurring due to hyperventilation during 
IPPV is due to mechanical effects.  
                 In addition to the hypertension which causes decrease in hepatic 
blood flow, liver also gets affected by anaesthetic agents like volatiles directly 
acting on the splanchnic blood flow. 
  
               Animal studies have shown that there is a reduction in cardiac output 
and mean arterial pressure. But the effect is more pronounced in the total 
hepatic blood flow and Portal blood flow with halothane. 
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             Also animal studies have shown that the hepatic O2 delivery gets 
reduced maximally by halothane. 
              When compared with inhalational agents, intravenous anaesthetic 
agents have shown only a modest decrease in hepatic blood flow and have 
produced no adverse influence on the post operative hepatic function. However 
this is based on limited clinical studies and trials. 
                There are studies in which they have found in fact that propofol had 
actually increased hepatic blood flow and portal venous blood flow which may 
be due to its direct vasodilator effects on the splanchnic circulation. 
                Though the volatile liquid agents have a tendency to decrease the 
hepatic blood flow, it has been found that deliberate hypotension seems to be 
well tolerated by the patients. So far there are no reports showing 
morbidity/mortality resulting from liver hypoperfusion during induced 
hypertension. 
RESPIRATORY SYSTEM 
             Positioning of the patients during the controlled hypotensive 
anaesthesia affects the pulmonary function and mechanics by the following 
ways: 
1. Pulmonary blood flow tends to gravitate to the dependent areas of the 
lung. Therefore there is a ventilation perfusion mismatch as the 
nondependent areas of the lungs are maximally ventilated. Hence the 
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amount of dead space increases. This gets exaggerated further in reverse 
trendelenburg position. 
2. The drugs causing hypotension (mainly vasodilators) for the controlled 
hypotensive anaesthesia inhibits the hypoxic pulmonary vasoconstriction 
response and causes an increase in the intrapulmonary shunt function. 
3. The result of these two mechanism is an increase in end total CO2 and 
hypoxaemia. This necessiatates the continuous monitorin of Paco2 during 
controlled hypotensive technique. Addition of higher Fio2 may be 
beneficial in this situation. 
TARGET BLOOD PRESSURE 
           The objective of the controlled hypotensive anaesthesia is to produce a 
bloodless field by reducing the blood loss. However the degree of hypotension 
depends on the individual. If the bleeding appears to be minimal and the vital 
organ perfusion is found to be adequate then the level of that hypotension can 
be considered satisfactory. Research have shown that if mean arterial pressure is 
kept alone the sum of colloid osmotic pressure and central venous pressure, 
blood flow to the organ shall be adequate the tissue needs. 
             Theoretically 32mmHg of mean arterial pressure is considered to serve 
this purpose but this is found to be below the safe limit propably because of the 
specific blood flow requirements of various organs and other diseases that had 
caused alteration in the circulation. 
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             The level of hypotension induced by hypotensive anaesthesia should be 
limited in such a way that it should reduce the bleeding in the operative field 
and in duration of the procedure seems to get benefited from it as long as the 
perfusion of various organs are adequate. 
             From the above studies and references, it has been suggested that 
controlling the hypotension to a level of 30% reduction of mean arterial 
pressure is considered safe. For ASA grade I patients it has been found that 
minimum of 50mmHg mean arterial pressure and in elderly a mean arterial 
pressure of 80mmHg is considered clinically acceptable. 
CONTRAINDICATIONS 
• Technique related 
• Lack of understanding 
• Limited experience 
• Lack of adequate patients monitoring 
• Patient related 
• Heart diseases 
• Diabetes mellitus 
• Anemia,polycythemia 
• Hemoglobinopathies 
• Hepatic diseases 
• CVA 
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• Kidney diseases 
• Systemic hypertension 
• Drug inolerence.      
RISKS OF CONTROLLED HYPOTENSION 
              The morbidity and mortality associated with hypotensive anaesthesia 
were as little as 1 in 31 and 1 in 291 respectively in a retrospective study done 
by Little et all in about 39000 cases . Compromise of the vital organ circulation 
is by far the commonest cause of mortality associated with hypotensive 
anaesthesia. Mortality may also be due to rebound hemorrhage, high spinal, 
effect of over heparinisation, arterial air embolism, pulmonary edema and 
pulmonary infarcts. 
             Many of the mortalities in the above study would have been probably 
due to the level of hypotension where the procedure was performed with a 
systolic blood pressure of <80mmHg. 
           In 1966  Eckenoffand in 1987  Madson have shown in their studies that 
the induced hypotensive anaesthesia technique can be considered safe if the 
limits are adhered to.  
LITERARY EVIDENCE FOR HYPOTENSIVE ANAESTHESIA: 
             Though unacceptable, mortality and morbidity have occurred in the 
study conducted by Little et al in 1954, it was found that it is the target systolic 
pressure which was kept below 80mmHg had caused that. Since then 50mmHg 
of target mean arterial pressure or higher set for ASA grade I patients. 
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             This new target has shown the advantages of the controlled hypotensive 
technique on the blood loss and the dry surgical field and ultimately the amount 
of transfusion requirements, with their target mean arterial pressure there were 
no significant difference in mortality/morbidity between hypertensive and 
normotensive patients. 
Gale Thompson et al in 1978 did a study and showed that the controlled 
hypotensive anaesthesia had significantly reduced the intraoperative blood loss 
and overall duration of the surgical procedure on patients scheduled for total hip 
arthoplasty. 
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BISOPROLOL 
 
Introduction  
In 1962,it was  Sir James Black  who first developed beta blockers at the 
Imperial Chemical Industries in the United Kingdom. 
Beta blockers are one among the four oral medications that has been 
proven in the clinical studies and trials to have decreased the cardiovascular 
morbidity and mortality.The life saving potential of beta blockers has been 
estimated to be around 33%. 
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Chemistry  
 Bisoprolol fumerate is a derivative of phenoxyaminopropanol. 
 
 It is a white crystalline substance which melts at a temperature of 101 
degree celcius. It is freely soluble in ethanol, water and methanol. Bisoprolol is 
less lipophilic than Propranolol but more than Atenolol. 
 pKa of  Bisoprolol base is 9.5 
Bisoprolol is available as 1.25 mg, 2.5 mg, 5 mg, and 10 mg tablets. 
Pharmacology and Biochemistry: 
Beta 1 selectivity 
 Bisoprolol has been proved to have a higher beta 1 selectivity when 
compared with Atenolol, Metaprolol and Betaxolol but less than that of  
Nebivolol. Bisoprolol has displayed 19 fold increased affinity for beta 1 
receptor versus beta 2 receptors which has been demonstrated in cloned human 
beta receptors. 
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Intrinsic sympathomimetic activity 
 Bisoprolol has got no intrinsic sympathomimetic activity as shown from 
the experiment in guinea pigs whose left  atrium of  their heart is pretreated with 
Reserpine and contractility measurements after electrical stimulation showed no 
evidence of  ISA. 
 Cardioprotective property of  Bisoprolol has also been demonstrated by 
an increase in the coronary perfusion pressure in anesthetized pigs. 
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Membrane stabilizing activity 
 Bisoprolol has a local anesthetic like action on the cornea of the rabbit 
and in the skin of guinea pigs but in a concentration several times higher than 
that required for blockade of beta receptors. 
Antihypertensive effect 
 Antihypertensive effects of Bisoprolol in conscious dogs with renal 
hypertension has been demonstrated with only a slight decrease in heart 
rate.Also it clearly reduced the development of  high blood pressure with 
chronic treatment in rats with spontaneous hypertension. 
Cardioprotection  
 In anesthetized open chest dogs, myocardial ischemia was induced by 
coronary occlusion and  it was found that a dose of 4 µg/kg Bisoprolol 
intravenous reduced the ST segment elevation induced by coronary occlusion 
by 60 %.This effect lasts for 40 mins after intravenous injection. 
Renin – Angiotensin system 
 Bisoprolol inhibits renin secretion stimulated by Isoprenaline. The release 
of renin was inhibited by about 65%.In addition to that Bisoprolol reduced the 
basal activity of renin. 
Duration of action 
 Bisoprolol has a long duration of action which is demonstrated in 
anesthetized  guinea pigs .After intravenous Bisoprolol and Propranolol the 
inhibition of Isoprenaline induced tachycardia was measured at various times. 
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 Drop in action duration curve is flatter for Bisoprolol than Propranolol. 
Side effects  
 Bisoprolol has no serious or unexpected side effects.sedative effects of 
Bisoprolol even after high single oral dose ( 30 mg and 100 mg/kg ) is less 
marked.This has been demonstrated in rats.Bisoprolol only slightly decreases 
the glucose tolerance in rats.This is observed at very high doses of Bisoprolol. 
 On repeated administration of Bisoprolol in adult normolipaemic rats 
absence of changes in lipid metabolism has been demonstrated. 
 No quantitative change in serum lipid is seen in young hyperlipaemic 
rats. 
Toxic effects 
 Bisoprolol is not cytotoxic or mutagenic. In higher doses embryotoxicity 
is demonstrated in animal studies.In a prolonged long term study conducted in 
dogs with  Bisoprolol in a dose of 30 mg/kg, a safety factor of  210 and  a 
safety factor of 525 is calculated in rats corresponding to the dose of 75 mg/kg. 
Acute toxicity 
 Lethal dose  ( LD50 ) of 1116 mg/kg for rats and 734 mg/kg for mouse 
has been demonstrated on oral administration. On intravenous administration 
values are found to be 24 mg/kg for dogs,127 mg/kg for mouse and 53 mg/kg 
for rats. 
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Short term toxicity 
 0.2,1.0  and 5 mg/kg were tolerated by rats.1.0,3.0 and 10 mg/kg were 
tolerated by dogs.For four weeks on daily intravenous administration, no signs 
of toxicological changes were found. 
Chronic toxicity 
 Daily doses of 15, 50 and 150 mg/kg for 6 months in rats has shown to 
have no toxic effects on oral administration. Slight reduction in body weight has 
been noted with  a dose of 75 mg/kg in a study conducted in rats. 
 
Specific toxic effects 
 In rabbits Bisoprolol administered in doses of 1.0,2.5 and 6.25 mg/kg and 
in rats given in doses of 15 and 40 mg/kg has been found to be safe. No 
teratogenicity or embryotoxicity is demonstrated . 
 In higher doses non beta blockers embryotoxicity must be taken into 
consideration. As per the study done on the rats and rabbits. 
 Safety of Bisoprolol has been demonstrated with  studies conducted on 
pregnant rats and rabbits which showed no influence in the postpartum period  
or partiurition,rearing,lactation and on the behavior of the offsprings. 
Mutagenic potential 
 In Chinese striped hamsters subjected to chromosome aberration tests in 
fibroblasts proved to be safe. No mutagenicity was found  either with 
mutagenicity tests with bacteria or micronucleus tests in mouse. 
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 In a long term study conducted in animals with Bisoprolol has showed no 
carcinogenicity. 
Contraindications 
Bisoprolol is contra-indicated in patients with: 
1.acute heart failure, episodes of heart failure decompensation requiring 
IV inotropic therapy,cardiogenic shock;  
2. second or third degree AV block (without a pacemaker); 
3. sick sinus syndrome or sinoatrial block; 
4.bradycardia with less than 60 beats/minute before the start of therapy; 
5. hypotension (systolic blood pressure less than 100mmHg); 
6.severe bronchial asthma or severe chronic obstructive pulmonary 
disease; 
7.late stages or peripheral arterial occlusive disease; 
8.Raynaud’s syndrome; 
9.Untreated phaeochromocytoma  
10.Metabolic acidosis; 
11.Hypersensitivity to bisoprolol or to any of the excipients included in 
the tablets. 
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PHARMACOKINETICS 
 The middle position of the Bisoprolol gives the pharmacokinetic property 
that has the features of lipophilicity ( which favours high absorption 
),hydrophilicity ( longer elimination half life and less first pass effect ) 
 
PHARMACOKINETICS DATA 
Absorption >90% 
Firstpass effect <10% 
Bioavailability 90% 
Cmax ~50ng/ml 
Tmax 2 – 3 hrs 
Elimination t ½ 10 – 12 hrs 
Clearance 50% unchanged 
50% metabolized 
Excretion 95% renal 
2% faecal 
Renal clearance 140 ml/min 
Distribution 3.2 l/kg 
Plasma protein binding ~30% 
Placental transfer Yes 
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Pharmacokinetics of  Bisoprolol is independent of age and sex. 
 Biotransformation is not accelerated even in hyperthyroidism. 
BIOAVAILABILITY 
 More than  90 % of the  drug is absorbed after oral administration.10 % 
of the drug undergoes first pass metabolism. So bioavailability of Bisoprolol is 
very high   ( 90 % ). 
DISTRIBUTION 
 Plasma protein binding of Bisoprolol is around 30 %. 
 Pathophysiological changes in plasma proteins (e.g increase in alpha 1 
glycoprotein ) do not influence the pharmacokinetics of  Bisoprolol. Since it is 
moderately lipophilic volume of distribution is medium and less protein binding 
capacity. 
METABOLISM & ELIMINATION 
 Two routes of clearance effective in Bisoprolol is by  
  1.Metabolism in the liver to inactive metabolites 
  2.Excretion of unchanged substances via kidneys. 
 This balanced clearance enables the half life of  Bisoprolol only to 
double, even in case of complete failure of either liver or kidney. So generally 
there is no need for adjustment of dose in mild to moderate liver or kidney 
impairments. However in chronic severe insufficiency of either of the two 
organs, daily dose of  Bisoprolol should not exceed 10 mg. 
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 With single daily dose of Bisoprolol for one week accumulation factor is 
1.2.Average first pass effect is 10 %.So accumulation and first pass effect is 
counteracted with single daily dose. 
 Elimination half life investigated in young healthy human volunteers     
(26 – 63 yrs) and in elderly hypertensives ( 69 – 80 yrs ) was always in the 
range of 10 – 12 hours. Peak plasma levels are noted after 1 – 3 hours of 
administration.So once daily dose regimen is very effective with Bisoprolol.  
Interactions  
 The effect of use of enzyme inducers/enzyme inhibitors on the half life of 
Bisoprolol is negligible. Half life is decreased by 35 % on rifampicin 
administration ( potent enzyme inducer ).Dose of Bisoprolol need not to be 
adjusted. Pharmacokinetics of Theophylline and Warfarin is not altered by 
Bisoprolol. Combining Bisoprolol with Procainaminde in patients with 
ventricular tachycardia prolongs the ventricular refractory period.So ventricular 
tachycardia treatment with this combination is proved to be effective. 
PHARMACOLOGY 
Hemodynamics  
 Several hemodynamic  studies have demonstrated that Bisoprolol to have 
less inotropic effect on heart. Two hours after 5 mg and 20 mg of oral 
Bisoprolol in coronary patients the hemodynamics were studied using 
radionuclide ventriculography and flow directed catheter in right ventricle. 
During rest and exercise there is decrease in heart rate, cardiac index and rate 
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pressure product after 5 mg of Bisoprolol.  The results were slightly different 
quantitatively after 20 mg of Bisoprolol. No significant effect in pulmonary 
capillary pressure or ejection fraction following two doses of Bisoprolol during 
rest and exercise. 
Electrophysiology  
 Adrenergic stimulation is inhibited by electrophysiological effects of beta 
blockers. Frequency of primary and secondary pacemaker centers is decreased. 
Delaying of AV conduction and prolongation of refractory period of AV node is 
noted. Ten patients with paroxysmal supraventricular tachycardia were 
investigated for electrophysiological process of  Bisoprolol after 10 mg of 
Bisoprolol administered intravenously as a single dose.Surface ECG potentials 
from right atrium and ventricle,Bundle of His are recorded before and after 
intravenous Bisoprolol. After intravenous Bisoprolol sinus node frequency is 
significantly decreased. Sinus node recovery time is significantly increased. AV 
node refractory period  was prolonged. Frequency corrected QT time is slightly 
decreased ,which  is suggestive of antiarrythmic effect in acute myocardial 
infarction. 
Receptor occupancy  
 In volunteers or patients  treated with beta blockers, percentage of beta 1 
receptor occupied is correlated directly with decrease in heart rate induced by 
exercise.  
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 In a double blind placebo controlled study groups, six patients were 
administered 200 mg of Atenolol and 100 mg Bisoprolol as a single oral dose. 
Percentage of beta 1 and beta 2 blockade was studied by ex vivo/invitro 
assays.80 % of beta 1 receptors and 25 % of beta 2 receptors were occupied 
with Atenolol group. With Bisoprolol group no beta 2 receptors were occupied. 
Thus higher beta 1 selectivity is demonstrated. 
Lung function 
 Even at peak plasma levels Bisoprolol has no clinically significant beta 2 
receptor occupancy. Bronchial muscle dilatation is mediated by beta 2 
receptors. Nonselective beta blockers poses risk in patients with COPD and 
asthma. Already existing increase in airway resistance is worsened and FEV1 is 
reduced.Ina controlled study done in COPD patients with Bisoprolol ( 30 and 40 
mg ) doeses outside the therapeutic range, minimal increase in airway resistance 
and decrease in FEV1 was measured. Within the therapeutic range ( 2.5 mg – 20 
mg ) beta 1 selectivity of  Bisoprolol has been proved. 
 Another study comparing placebo, Atenolol and Bisoprolol in coronary 
artery disease patients with COPD airway resistance was measured. Airway 
resistance remained unchanged with placebo and Bisoprolol group. Slight 
increase in airway resistance was noted in Atenolol group. 
Peripheral circulation 
 Influence of beta blockers on isoprenaline induced increased blood flow 
and decreased diastolic blood pressure was studied as a measure of receptor 
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selectivity (bela 1).Non selective beta blockers significantly reduces these 
isoprenaline effects .But very negligently by Bisoprolol. In a study with 16 
healthy volunteers dose response curves for isoprenaline were derived for fall in 
diastolic blood pressure prior to and after intravenous beta 1selective drugs 
(Bisoprolol, Metaprolol ),beta 1 selectivity with intrinsic sympathomimetic 
activity ( Acebutalol ),non selective drugs with intrinsic sympathomimetic drugs 
(Penbutalol) and non selective beta blocker (Propranolol ). All the beta blockers 
reduces the heart rate during exercice to almost an equal extent. Shift to right of 
the dose response curve determines the highselectivity ( beta 1 ) which is noted 
with Bisoprolol, Metaprolol and Acebutalol. 
Lipid metabolism 
 Non selective beta blockers have adverse effects on lipid metabolism. 
They increase the total and LDL cholesterol levels and decreases the HDL 
levels ( protective against atheroma ).In long standing treatment with Bisoprolol 
has no change in either of the cholesterol levels. In a double blind placebo 
controlled study done in patients with hypertension and type II diabetes mellitus 
, serum levels of cholesterols and triglycerides were measured. No significant 
change in lipid levels were observed with Bisoprolol ( 10 mg ) when compared 
with placebo. Results of the study done with long term treatment of  Bisoprolol 
shows no significant change in lipid parameters. 
 Also  studies on lipolysis, after treatment with terbutaline (beta 2 agonist) 
Bisoprolol showed no effect on free fatty acid levels. Bisoprolol at a dose  of 5 
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mg showed no action on beta 2 receptors. These results are confirmed by studies 
done over 5 years. 
Carbohydrate metabolism 
 Bisoprolol due to its high beta 1 selectivity does not affect the 
carbohydrate metabolism. In diabetic patients treated with Bisoprolol dose 
adjustments of oral hypoglycemic or additional blood sugar monitoring is not 
needed.In a study, healthy volunteers were administered various beta blockers 
orally and followed by insulin after 3 hours.No change in duration of 
hypoglycemia ,serum lactate concentration was observed with 10 mg  
Bisoprolol when compared with the control group. 
Insulin sensitivity 
 Beta blockers adversely affect the glucose levels and increases the insulin 
resistance. Tests which measures glucose uptake is taken as a measure of insulin 
sensitivity. Such tests showed no adverse effect on sensitivity of insulin with 
Bisoprolol. 
 In a double blind study done in 22 healthy volunteers who were 
administered either ACE inhibitors (Lisinopril) or selective beta 1 blocker 
(Bisoprolol ) for four weeks. Serum insulin concentration and glucose infusion 
rate were measured. No significant change is noted in either group. 
 In conclusion neither group had influenced the insulin sensitivity in 
normotensive patients. 
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Fibrinolytic system 
 Circadian variability is noted in sympathetic activity and fibrinolytic 
system components. This explains the highest risk of coronary occlusion in the 
morning when the activity of tissue plasminogen activator and plasminogen 
activator inhibitor 1 is at its peak and produce a prothrombotic state. In patients 
treated with beta blockers attenuation of the circadian rhythm is noted in 
patients with myocardial infarction. In a study conducted in 20 coronary artery 
disease patients whose disease was in a stable state ( stable plaque ) were 
administered placebo, Bisoprolol ( 10 mg/day  and increased to 20 mg/day if 
basal heart rate is more than 60 per min ), Quinapril ( 10 mg/day  and increased 
to 20 mg/day if basal heart rate is more than 60 per min ) each for 4 weeks 
consecutively. After every 4 weeks period 6 hourly blood samples,24 hours 
Holter monitoring were done. Heart rate variability was significantly increased 
with Bisoprolol. Peak plasminogen activator inhibitor 1 activity which is seen in 
the morning is decreased  by Bisoprolol though not statistically  significant. 
Quinapril had no effect in either of the parameter. 
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REVIEW OF LITERATURE 
 
Various studies have evaluated the efficacy of Bisoprolol in the 
management of hypertension and heart failure and many studies have 
demonstrated the importance of bloodless surgical field using various drugs and 
combinations. 
 
In a study by Matsuoka H,Kuwajima I and Shimada K, they have 
compared the efficacy and safety of Bisoprolol transdermal patch and oral 
formulation in controlling the grade I or II essential hypertension.They included 
both sexes with age ranging from 20-80yrs with grade I or II essential 
hypertension in their study.They concluded that both transdermal patch as well 
as the oral formulation of Bisoprolol are superior to Placebo in controlling 
blood pressure. 
 
In a study by Andre P.Boezaart and Johan Van der Merwe,they compared 
the efficacy of Sodium Nitroprusside and Esmolol in providing an optimal 
surgical field and better control of the blood pressure intraoperatively done in 
20 consenting ASA I & II patients.They concluded that Esmolol provided 
optimal surgical field than SNP stating that hypotension caused by 
cardioselective beta blockers resulted in increased sympathetic tone of the 
mucous membrane arterioles that exerted unopposed alpha-adrenergic effects on 
the mucous membrane vasculature, causing  capillary vasoconstriction.On the 
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other hand SNP produced arteriolar vasodilatation which may explain the poor 
surgical condition produced by it. 
In an another study, Goran Kekovic and Branislav Milovanovic have 
compared the effect of Bisoprolol and Losartan in the treatment of essential 
hypertension.In their study they included both sexes age ranging from 26-75 yrs 
with essential hypertension and evaluated and compared the efficacy of 
Bisoprolol and Losartan in a oral dose of 5mg and 50mg respectively. They 
concluded that both the drugs effectively regulated the blood pressure. 
 In a study done by Nitu Puthenveettil and Sunil Rajan, they have 
evaluated the hemodynamic changes and surgical conditions by comparing oral 
premedication with Clonidine and Metoprolol. In their study they had given the 
drugs 2 hrs before surgery and evaluated the heart rate and blood pressure every 
15 mins till the end of surgery. And also they estimated the quality of surgical 
field with a pre-defined category scale with scores 1 – 5 . 
 In an another study by Tarek Shams and Nahla S El Bahnasawe,they 
compared and evaluated the efficacy of Dexmeditomidine and Esmolol in 
FEES.The study was done on 40 ASA I & II patients scheduled for FESS 
receiving either Dexmeditomidine or Esmolol.The surgical field was assessed 
using Average Category Scale and the parameters observed were HR,MAP and 
intraoperative Fentanyl consumption. They concluded that both 
Dexmeditomidine and Esmolol can be safely used in FESS to provide a better 
surgical field and better control of blood pressure.  
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METHODOLOGY 
This study was a randomized, prospective double blinded clinical trial 
conducted over a period of  1 year  in the  Department of  Anesthesiology at 
Madurai Medical College, Madurai. 
Inclusion criteria : 
 1.Functional Endoscopic Sinus Surgeries 
 2.Both sexes. 
 3.Age between 15 – 65 years 
 4.ASA Grade I & II 
Exclusion criteria : 
 1.Patients with history of Hypertension 
 2.Patients with history of Asthma 
 3.Patients with history of Heart blocks 
 4.Patients with history of  Bleeding disorders 
 5.Patients taking Antiplatelet drugs or Antihypertensive drugs 
 6.Patients with known Allergy or hypertensive reactions to medications   
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METHODS 
After getting consent from each patients and Institutional Ethical 
Committee  approval, 60 patients of age between 15 – 65 years belonging to 
ASA Grade I & II who are posted for Functional Endoscopic Sinus Surgery 
were randomized into one of the two groups. Group A ( receiving placebo ) and 
group B ( receiving bisoprolol ) of 30 each for induction and maintenance of 
anesthesia ( sample size was taken in accordance with the similar type of studies 
done in the past ). 
All patients underwent a thorough pre – anesthetic assessment on the 
evening before the day of surgery. A thorough medical and surgical history was 
taken and all the required investigations were reviewed. detailed  and valid 
informed consent was obtained from each patient after explain the procedure. 
In the morning of surgery all patients received Inj.Glycopyrollate 0.2 mg 
and Inj.Midazolam 1 mg as premedication. All patients were fasting for atleast  
8 hours before the start of the surgery. Group B patients were given Bisoprolol 
2.5 mg orally with a sip of water 90mins before the surgery by an assistant as 
the anesthesiologist was blinded to the randomization. 
After the patients were wheeled inside the operating room, a large bore 
intravenous canula (18G) was inserted on the left upper limb. All patients 
received crystalloid infusion as standard. Monitoring include 
ECG,Pulseoximetry, ETCo2 and non invasive blood pressure . 
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Anesthetic management of all patients were similar. Before 
inductionpatients were preoxygenated with 100 % oxygen for a period of 3mins 
followed by induction with Inj.Thiopentone in a dose of 5 mg/kg, Inj.Fentanyl 
in a dose of 2µg/kg and Inj.Atracurium 0.5 mg/kg. Patients were intubated with 
a suitable sized cuffed endotracheal tubes. Throat was packed with tape gauze to 
prevent microaspirations. All patients received crystalloid infusion at a rate of   
4 ml/kg/hr. Patients were positioned supine with about 30 degree head 
elevation. 
The surgeons used 2% Lignocaine with Adrenaline in the concentration 
of  1in 2,00,000 dilution for the nasal mucosa infiltration. Maintainance was 
with O2 and N2O in the percentage of 40 and 60 respectively  and Sevoflurane. 
The target MAP was around 60 – 70 mmHg during the surgery and was 
left to the anesthesiologist who is conducting anesthesia to judge the clinical 
situation  and to adjust the concentration of Sevoflurane and the additional 
doses of Fentanyl. All patients received Inj.Dexamethasone 4 mg and 
Inj.Ondansetron 4 mg after the start of the procedure. 
After the surgery is over,patients were reversed with Inj.Neostigmine 
0.05 mg/kg dose and Inj. Atropine 0.02 mg/kg dose. Patients were shifted to the 
PACU and were observed for an hour and then shifted to the respective wards. 
Postoperative hemoglobin estimation was done on the evening of the day of 
surgery.  
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During the surgery, Sevoflurane volume percentage, MAP and HR were 
recorded every 10mins.The blood loss was estimated from the number of 
soaked cotton strips and the volume of blood lost in the suctioning apparatus 
which was kept empty before the start of the surgery. 
A fully soaked cotton strip was estimated to contain 5 ml of blood and a 
partially soaked cotton strip was estimated to contain 2.5 ml of blood. 
After the procedure was over, surgeons who performed the surgery were 
asked about the  condition of  the operating field and to grade it using the 
FROMME BOEZAART Scale. 
 
FROMME – BOEZAART GRADING 
Grade 0 No bleeding 
Grade 1 Slight bleeding. 
No suctioning required 
Grade 2 Slight bleeding. 
Occasional suctioning required. 
Bleeding does not threaten surgical field 
Grade 3 Slight bleeding. 
Frequent suctioning required. 
Bleeding threatens surgical field for a few seconds after 
removal of suction 
Grade 4 Moderate bleeding. 
Frequent suctioning required. 
Bleeding threatens surgical field immediately after removal 
of suction 
Grade 5 Severe bleeding 
Constant suctioning required 
Bleeding appears faster than can be removed by suction 
Surgical field threatened and surgery not possible 
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OBSERVATION AND RESULTS 
 
STUDY DESIGN  
 In the present study,60 patients with age between 15 – 65 years belonging 
to ASA Grade I & II were randomly allocated into two groups each consisting 
of 30 patients. 
 Group A – patients receiving placebo 
 Group B – patients receiving Bisoprolol. 
 The age , sex, preoperative hemoglobin of all patients were comparable 
between the two groups. 
STATISTICAL TOOLS 
 The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
statistical package for the social sciences ( SPSS software version 16 ). 
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and 'p' values were calculated. Kruskul Wallis chisquare 
test was used to test the significance of difference between quantitative 
variables and Yate’s chi square test for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship. 
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SEVOFLURANE CONSUMPTION CALCULATION 
 
The densityof  Sevoflurane is 1.520.That is 1 ml of sevoflurane weighs 
1.520 grams. 
Sevoflurane molecular weight is 200 grams which is the weight of 1 
mole of Sevoflurane. 
So if 200 grams of Sevoflurane has 1 mole then 1.520 grams ( 1 ml ) will 
have 0.0076 moles.( 1.520/200 ). 
According to the universal gas equation 1 mole of an ideal gas will 
liberate 22.4 liters of vapour at STP.  
So 1 ml of Sevoflurane which has got 0.0076 moles will convert to 
170.24 mls of Sevoflurane vapour.( 22400  × 0.0076 ) 
1 mole will liberate 22400 ml of vapour. 
1 ml will liberate 170 mls of vapour .( 22400 x 0.0076 ) as 1 ml contains 
0.0076 mloes. 
Fresh gas flow (L/min) x Dial concentration (%) = ml of vapour/min 
To liberate 170 ml of vapour 1 ml is used. So 
1/170 x ml of vapour/min = ml of Senoflurane used  ( or ) 
1/170 x Fresh Gas Flow(ml/min) x Dial concentration = liquid 
Sevoflurane in ml. (or ) 
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 Fresh Gas Flow ( L ) x Dial Concentration ( % ) x 10/170 ( or ) 
Fresh Gas Flow ( L ) x Dial Concentration ( % ) x 0.06 = ml of 
Sevoflurane. 
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Table : AGE DISTRIBUTION 
 
GROUPS Age P value 
 
CONTROL 
 
34.96 ± 12.69 
 
 
BISOPROLOL 
 
32.73 ± 11.87 
 
 0.35 
 
  
 In Group A the mean age was 34.96 ± 12.69 and in Group B the mean 
age was 32.73 ± 11.87.The p value was 0.35 which was not statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
COMPARISON OF AGE DISTRIBUTION BETWEEN THE TWO GROUPS 
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Table 2: SEX DISTRIBUTION 
 
 
GROUPS 
 
MALE 
 
FEMALE 
 
 
TOTAL 
 
P Value 
 
CONTROL 
 
16 
 
 
14 
 
 
30 
 
 
BISOPROLOL 
 
18 
 
 
12 
 
 
30 
 
 
TOTAL 
 
34 
 
 
26 
 
 
60 
 
.602 
 
  
 Nearly 56.66 % of the study were males and 43.33 % were females 
among the study population. Sex composition of both the groups were similar in 
both the groups. p value is 0.602 which was not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
COMPARISON OF SEX DISTRIBUTION BETWEEN THE TWO GROUPS 
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Table 3 :PREOPERATIVE HAEMOGLOBIN 
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
10.86 
 
0.563 
 
 
BISOPROLOL 
 
 
11.05 
 
0.635 
 
 
 
0.12 
 
 
 
 
 In Group A the mean preoperative hemoglobin was 10.86 ± 0.563 and in 
Group B it was 11.05 ± 0.635.The p value is 0.12 which is not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
COMPARISON OF PREOPERATIVE HEMOGLOBIN 
BETWEEN THE TWO GROUPS 
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Table 4:DURATION OF SURGERY 
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
75.66 
 
10.48 
 
 
BISOPROLOL 
 
 
67.0 
 
5.81 
 
 
 
< 0.0001 
 
 
 
 The mean duration of surgery in Group A was 75.66 ± 10.48 and in 
Group B it was 67.0 ± 5.81.The p value is < 0.0001 which is statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
COMPARISON OF DURATION OF SURGERY   
BETWEEN THE TWO GROUPS 
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Table 5 :BLOOD LOSS DURING THE SURGERY  
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
97 
 
16.75 
 
 
BISOPROLOL 
 
 
58.3 
 
13.9 
 
 
 
< 0.0001 
 
 
 
 
 In Group A the mean blood loss during the surgery was 97 ± 16.75 and in 
Group B the mean blood loss was 58.3 ± 13.9.The p value is < 0.0001 which is 
statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
COMPARISON OF BLOOD LOSS DURING THE SURGERY  
BETWEEN THE TWO GROUPS 
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Table 6: POST OPERATIVE HEMOGLOBIN  
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
9.5 
 
0.65 
 
 
BISOPROLOL 
 
 
10.63 
 
0.65 
 
 
 
< 0.0001 
 
 
 
 The mean post operative hemoglobin in Group A was 9.5 ± 0.65 and in 
Group B it was 10.63 ± 0.65.The p value  is< 0.0001 which is statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
COMPARISON  POSTOPERATIVE HEMOGLOBIN  
BETWEEN THE TWO GROUPS 
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Table 7: DIFFERENCE IN HEMOGLOBIN 
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
1.04 
 
0.22 
 
 
BISOPROLOL 
 
 
0.5 
 
0.21 
 
  
< 0.0001 
 
 
 
 The mean difference in haemoglobin in Group A was 1.04 ± 0.22 and in 
Group B was 0.5 ± 0.21.The p value is < 0.0001 and is statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
COMPARISON OF DIFFERENCE IN HEMOGLOBIN  
BETWEEN THE TWO GROUPS 
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Table 8 
COMPARISON OF MAP VALUE BETWEEN TWO GROUPS 
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
p Value 
 
CONTROL 
 
 
92.87 
 
6.39 
 
 
BISOPROLOL 
 
 
78.25 
 
3.5 
 
 
 
< 0.0001 
 
 
 
In Group A the mean MAP value was 92.87 ± 6.39 and in Group B it was 
78.25 ± 3.5.The p value is < 0.0001 which is statistically significant. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
COMPARISON OF MAP VALUES  BETWEEN THE TWO GROUPS 
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 Groups n Mean Std. Deviation 
Std. Error 
Mean 
P 
VALUE 
MAP PRE OP Bisoprolol 30 73.3000 6.67548 1.21877 0.000 
Control 30 86.2667 6.32964 1.15563 
MAP 10 MINS Bisoprolol 30 74.3000 5.25324 .95911 0.000 
Control 30 87.9000 5.39700 .98535 
MAP20 MINS Bisoprolol 30 74.2667 6.23634 1.13859 0.000 
Control 30 86.2667 5.83647 1.06559 
MAP30 MINS Bisoprolol 30 73.4000 5.58076 1.01890 0.000 
Control 30 88.7333 6.41622 1.17144 
MAP 40 MINS Bisoprolol 30 74.0667 4.89851 .89434 0.000 
Control 30 89.2000 5.73194 1.04650 
MAP 50 MINS Bisoprolol 30 74.2000 4.56675 .83377 0.000 
Control 30 86.9333 4.82760 .88140 
MAP 60 MINS Bisoprolol 30 72.9000 4.61146 .84193 0.000 
Control 30 91.0333 5.17609 .94502 
MAP 70 MINS Bisoprolol 15 72.4000 5.15198 1.33023 0.000 
Control 20 89.0500 5.88911 1.31684 
 
Group Statistics showing MAP variation between the two groups. 
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Table 9: COMPARISON OF HEART RATE 
 BETWEEN THE TWO GROUPS. 
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
94.75 
 
3.14 
 
 
BISOPROLOL 
 
 
67.97 
 
1.84 
 
 
 
< 0.0001 
 
 
 
In Group A the mean HR was 94.75  ±  3.14  and in Group B the mean 
HR was 67.97  ± 1.84.The p value is < 0.0001 and it is statistically significant. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
COMPARISON OF HEART RATE VARIATION 
BETWEEN THE TWO GROUPS 
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Group Statistics showing Heart Rate variation between two groups 
 
 
 
 
 
 
 
 
 
 Study Groups N Mean Std. Deviation 
Std. Error 
Mean p VALUE 
HR  PRE 
OP 
Bisoprolol 30 70.8000 4.72265 .86223 .000 
Control 30 94.1333 6.84676 1.25004 
HR 10 
MINS 
Bisoprolol 30 69.3667 5.26199 .96070 .000 
Control 30 95.8333 5.79586 1.05817 
HR 20 
MINS 
Bisoprolol 30 67.3667 4.00416 .73106 .000 
Control 30 95.1000 5.39060 .98419 
HR 30 
MINS 
Bisoprolol 30 68.5333 5.11747 .93432 .000 
Control 30 95.7000 4.94208 .90230 
HR 40 
MINS 
Bisoprolol 30 67.9000 5.07428 .92643 .000 
Control 30 93.0000 6.05720 1.10589 
HR 50 
MINS 
Bisoprolol 30 66.5000 5.60018 1.02245 .000 
Control 30 95.1667 5.47145 .99895 
HR 60 
MINS 
Bisoprolol 30 66.7333 4.80613 .87747 .000 
Control 30 95.2000 5.83332 1.06501 
HR  70 
MINS 
Bisoprolol 16 65.6875 3.47791 .86948 .000 
Control 21 93.1905 4.68635 1.02265 
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Table 10 
COMPARISON OF SEVOFLURANE VOLUME % USED  
BETWEEN TWO GROUPS 
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
2.03  
 
0.25 
 
 
BISOPROLOL 
 
 
1.11 
 
0.11 
 
  
< 0.02 
 
 
 
In Group A the mean sevoflurane volume percentage used was 2.03 ± 
0.25 and in Group B the mean value was 1.11 ± 0.11.The p value is  < 0.02 and 
it is statistically significant. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
COMPARISON OF VOLUME PERCENTAGE OF  
SEVOFLURANE USED  BETWEEN THE TWO GROUPS 
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Table 11: COMPARISON OF LIQUID SEVOFLURANE 
USED BETWEEN THE TWO GROUPS 
 
 
GROUPS 
 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
37.3  
 
2.2 
 
 
BISOPROLOL 
 
 
18.58 
 
3.1 
 
  
< 0.0001 
 
 
 
The mean volume of liquid sevoflurane used in Group A is 37.3 ± 2.2 ml 
and in group B it is 18.58 ± 3.1.The p value is < 0.0001 which is statistically 
significant. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
COMPARISON OF VOLUME OF LIQUID SEVOFLURANE  
USED  BETWEEN THE TWO GROUPS 
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Table 12: COMPARISON OF FENTANYL REQUIREMENT 
BETWEEN THE TWO GROUPS 
 
 
 
GROUPS 
 
Mean 
 
Std. Deviation 
 
P Value 
 
CONTROL 
 
 
133.33  
 
22.5 
 
 
BISOPROLOL 
 
 
122 
 
11.87 
 
  
< 0.02 
 
 
 
 
In Group A the mean value of Fentanyl used was 133.33 ± 22.5 and in 
Group B it was 122 ± 11.87.The p value is < 0.02 which is statistically 
significant. 
 
 
 
 
 
 
 
  
 
 
COMPARISON OF FENTANYL USED  BETWEEN THE TWO GROUPS 
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Table 13: COMPARISON OF FROMME – BOEZAART SCALE 
BETWEEN THE TWO GROUPS. 
 
Formme Boezaart Score  
 
FB Score Study Groups 
Total Bisoprolol Control 
Slight Bleeding No suctioning 5 0 5 
Slight Bleeding , suctioning+, No 
obliteration of operative feild 20 3 23 
Slight Bleeding Frequent suctioning 5 14 19 
Moderate bleeding 0 10 10 
Heavy bleeding 0 3 3 
Total 30 30 60 
 
 
In Bisoprolol group 5 patients had slight bleeding with no need for 
suctioning , 20 patients had slight bleeding which required occasional 
suctioning , 5 patients had slight bleeding which required frequent suctioning 
and none had moderate to severe bleeding. In Group A 10 and 3 patients had 
moderate and severe bleeding respectively. The p value is < 0.0001 and is 
statistically significant. 
 
 
  
 
 
 
COMPARISON OF FROMME BOEZAART SCALE  
BETWEEN THE TWO GROUPS 
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DISCUSSION 
 
FESS is one of the well accepted treatment modalities ( rhinosurgeries ) 
for the chronic inflammatory sinus diseases. FESS is done by introducing a high 
definition telescope into the nasal cavity through the anterior nares. As the nasal 
cavity is a very sensitive one ,any surgical manipulation of  the area can result 
in severe sympathetic stimulation which would cause tachycardia and 
hypertension.  In addition to that the nasal mucosa has got a very rich network 
of blood supply and very delicate to touch in nature it would bleed easily which 
severely compromises the visualization of the operating field. This becomes 
even more difficult with the use of endoscopes. As a result of  this there could 
be an inadvertent tissue injury which leads to postoperative adhesions and even 
scarring. At the worst it can lead to severe complications such as orbital or brain 
injury. 
This necessitates a blood less field for the surgeon to operate upon easily 
so as to minimize the complications. 
Various techniques have been used during FESS to achieve a bloodless 
field and an acceptable operating condition, including local anesthesia, TIVA 
and inhalational anesthesia. Many of these techniques are not without 
complications. Adrenaline used along with local anesthesia for the infiltration of 
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the nasal mucosa causes local vasoconstriction and reduces bleeding for a short 
period of time but at the cost of transient hypertension and tachycardia. 
Reducing the inflammatory process of the disease by using steroids for 
several preoperative days can also reduce the bleeding during surgery. Other 
drugs like Propofol, Dexmeditomidine and Remifentanil have also been used to 
reduce the bleeding which provides an optimal surgical field However the 
expenditure and the availability of these drugs could be a factor to be 
considered. 
To minimize the intraoperative bleeding at the surgical field reduction of 
the arterial blood pressure is required. This is achieved by either increasing the 
concentration of the volatile anesthetic agent or with the use of  vasodilator 
drugs like Sodium nitroprusside. But with these techniques reflex tachycardia is 
a common side effect which increases the venous oozing in the surgical field. 
This is because the extent of bleeding in the operative field not only depends on 
the MAP but also on the venous pressure and capillary blood flow. 
Studies have suggested that if the heart rate is decreased it increases the 
diastolic filling time and lowers the venous pressure and causes reduced venous 
oozing at the surgical field. 
In this study the MAP values during the surgery were  92.87 ± 6.39 and 
78.25 ± 3.5 in Group A and Group B respectively. This is statistically 
significant. Heart rate of the patients were  67.97 ± 1.84 and  94.75 ± 3.14 in 
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Bisoprolol group and  Control group respectively which is also statistically 
significant. 
From this observation, it seems likely that the blood loss can be directly 
correlated with the heart rate. 
Also the anesthetic requirements such as Sevoflurane and Fentanyl are 
found to be higher in the control group. 
The usage of beta blocker to lower the heart rate and blood pressure 
reduces the bleeding and improves the visualization of the surgical field. 
Metaprolol and Esmolol have been used for this purpose and did reduce the 
bleeding. However the effect lasted for a short period of time as these drugs 
belong to the short acting beta blockers. Also these drugs caused a rebound 
bleeding due to increased heart rate and venous pressure after the effect wore 
off. Continuous infusion of  Esmolol can also be used to produce same effect 
throughout t the surgery but a more simpler, easier and single dose orally would 
be considered both prudent and cost effective. 
This clinical trial was done to study the effect of  Bisoprolol a long acting 
beta blocker, orally in reducing the bleeding and improvement in the surgical 
field during FESS. 
The blood loss during surgery was lower with Bisoprolol group as 
compared with control group which is statistically significant. The reason for 
this could be: 
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1. Due to the negative chronotropic action of Bisoprolol which reduces the 
frequency of arterial pulsations and thereby causing less exudation  of 
blood per unit time from the injured vessels. 
2. The resultant reduction in the heart rate increases the diastolic filling time 
leading to reduced venous pressure and thus the venous oozing. 
 
In  this  study the dose of  Bisoprolol was only 2.5 mg orally which 
should not cause any untoward serious side effects. 
The patients in Bisoprolol group needed lower doses of  both liquid 
Sevoflurane as well as Fentanyl which was statistically significant and provided 
a clinical and financial benefit.The volume of  liquid Sevoflurane used were 
37.3 ± 2.2 ml and 18.58 ± 3.1in control group and Bisoprolol group respectively 
which is statistically significant. 
Opinion was obtained from the operating surgeon at the end of the 
surgery about the surgical field and this was graded according to the FROMME-
BOEZAART  Scale. A direct real time correlation between the hemodynamic 
parameters like MAP, heart rate and the surgical field was not made in this 
study as it would  distract the surgeon concentration. The overall operatong time 
was reduced because of the reduced bleeding and better view of the field. 
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SUMMARY 
 
This is prospective, randomized double blided controlled study involving 
60 cases posted for Functional Endoscopic Sinus Surgeries under general 
anesthesia. They were divided into two groups, Group A receiving Placebo and 
Group B receiving Bisoprolol 2.5 mg orally. Bisoprolol was given by an 
assistant 90 mins before surgery with sip of water. The following parameters 
were noted during the study period. The anesthetic requirements of  Sevoflurane  
and Fentanyl, grading of the surgical field by the surgeons, volume of  blood 
lost and difference in the preoperative and postoperative hemoglobin. The 
hemodynamic parameters noted are MAP and heart rate, oxygen saturation with 
pulseoximeter. 
 
According to the present study ,it was noted that the anesthetic 
requirement of  both Sevoflurane and Fentanyl were lower in the Bisoprolol 
group. There was reduced bleeding in the surgical field in the Bisoprolol group. 
And also the surgical field was found to be optimal in the Bisoprolol group as 
stated by the operating surgeons. This was reflected in the difference between 
the preoperative and postoperative hemoglobin. There was a significant 
reduction in the MAP and HR with the Bisoprolol group. 
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Therefore this clinical study has demonstrated that the use of  a single 
preoperative oral dose of  Bisoprolol 2.5 mg can reduce the intraoperative 
bleeding during FESS significantly and also  improves the visualization of the 
surgical field. Also it lowers the anesthetic requirements of  Sevoflurane and  
Fentanyl. 
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CONCLUSION 
 
In conclusion ,the data obtained and statistical analysis suggest that  the 
bleeding is significantly  less with Bisoprolol when compared with 
placebo.Improvement  in the surgical field is significantly better with  
Bisoprolol.The hemodynamic variables like MAP and heart rate were 
significantly low when compared with placebo.There is a significant reduction 
in the anesthetic requirement of  Sevoflurane and Fentanyl with Bisoprolol. 
Bisoprolol can be used as an alternative drug in controlled hypotension by 
which the patients are benefitted clinically and financially. 
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PROFORMA 
 
NAME  :                                                              I.P.NO :                            
ASA : 
AGE & SEX : 
WEIGHT    : 
DATE & TIME  OF ADMISSION:                                   
DATE & TIME OF DISCHARGE: 
 DIAGNOSIS: 
PROCEDURE: 
HISTORY:  
Allergy to drugs, 
Bleeding  disorders,  
H/o Hypertension,Asthma,Heart blocks. 
CLINICAL EXAMINATION: 
PR, BP, SPO2,   
RS, CVS 
BASIC INVESTIGATIONS: 
  Haemoglobin, PCV 
  Renal parameters &Serum  electrolytes,   
   ECG 
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ANAESTHETIC TECHNIQUE:  
All patients are induced with Inj.Thiopentone 5mg/kg and Inj.Atracurium 
0.5mg/kg after preoxygenation with O2 5L/min for 5mins.Anesthesia was 
maintained with 66% N2O and 33% O2.All patients received Inj.Fentanyl 2 
µg/kg initially. 
              MONITORING OF VITALS EVERY 15 MINS TILL THE END OF 
SURGERY: 
             DURATION OF SURGERY: 
             ADDITIONAL INJ.FENTANYL NEEDED: 
             DIAL CONCENTRATION OF SEVOFLURANE EVERY 15 MINS: 
             FRESH GAS FLOW: 
 
 
 
 
 
 
 
 
 
 
S.No Name Age Sex IP No Pre-op Hb Post-op Hb Diff Duration Blood loss FB Scale Sevo Vol% Liquid Sevo Fentanyl
1 MURUGAN 18 M 45345 10.2 9.2 1 100 90 3 1.2 27 160
2 SELVI 18 F 5452 10.6 9.6 1 70 85 3 1 26.4 160
3 JEGAN 20 M 4575 9.8 9 0.8 65 80 2 0.8 21 140
4 SURESH 24 M 2452 10 9.2 0.8 90 110 4 0.75 20.5 160
5 ALAGAN 45 M 12452 11.2 9.8 1.4 85 120 4 1.5 30 160
6 SAMI 45 M 4242 10 8.8 1.2 90 110 4 1.2 28 140
7 THOTTICHI 40 F 2422 10.4 9.4 1 95 95 3 1.4 28.4 120
8 KRISHNAN 52 M 45212 10.6 9.7 0.9 70 120 4 0.9 26.4 160
9 RAJESWARI 38 F 24252 9.8 9 0.8 65 100 3 0.86 26 140
10 LAKSHMI 38 F 24524 9.8 8.9 0.9 70 90 3 0.88 26.4 120
11 KANDHI 40 F 68785 10.2 9 1.2 75 80 2 0.75 26 110
12 VIRALI 55 F 8574 11 9.6 1.4 80 120 4 1 28 160
13 MALACHAMY 42 M 47564 11.2 10.2 1 80 80 2 0.8 27.2 110
14 SENTHIL 30 M 75785 10.8 9.8 1 75 75 2 0.78 26.4 110
15 PAKIYAM 39 F 57552 11.4 10.2 1.2 65 120 4 1.2 28.2 160
16 RAJESH 15 M 52752 10.8 9 0.8 85 110 4 1 28 120
17 PALANI 42 M 75755 9.8 9 0.8 80 120 5 1.5 29 160
18 PAECHI 46 F 5752 9.6 8.7 0.9 65 65 2 0.78 26 100
19 SARAVANAN 35 M 75752 10.2 9 1.2 60 75 3 0.76 24.8 110
20 MUTHU 40 M 44242 10.4 9 1.4 70 110 5 1.2 29 160
21 VALLI 43 F 72427 11.8 10.8 1 70 110 4 1 28.6 100
22 KUMARI 18 F 4204 11.6 10.8 0.8 85 75 3 0.82 27.6 140
23 SELVI 19 F 4255 9.8 8.9 0.9 80 100 4 1 28 110
24 PRAKASH 22 M 75275 10.2 9 1.2 70 80 3 0.84 28.2 110
25 VINOTH 42 M 75275 10.4 9 1.4 65 85 3 0.92 28.6 110
26 SELVARAJ 21 M 24525 10.6 9.6 1 60 95 4 0.96 29 120
27 VENI 55 F 524241 11.2 9.8 1.4 75 90 3 0.84 28.2 110
28 ANDAL 57 F 52558 11.4 10.6 0.8 65 120 5 1.5 29.8 160
29 MEENAKSHI 24 F 58545 11.6 10.8 0.8 85 110 4 1.5 30 140
30 PRABHU 26 M 25554 10.4 9.2 1.2 80 100 3 1.2 28.8 140
CONTROL GROUP
S.No Name Age Sex IP No Pre-op Hb Post-op Hb Diff Duration Blood loss FB Scale Sevo vol% Liquid Sevo Fentanyl
1 SENTHIL 16 M 56335 10.4 9.8 0.6 75 50 2 0.75 20.25 140
2 JOSEPH 18 M 75375 11.2 11 0.2 60 50 2 0.64 8.75 120
3 PRIYA 22 F 53275 10.6 10 0.6 60 60 2 0.7 78.6 120
4 SUGANTHI 33 F 25478 10.2 9.8 0.4 65 60 2 0.78 21 100
5 PRIYA 39 F 24525 11 10.2 0.8 70 65 2 0.8 21.6 120
6 BALA 26 M 25557 11.8 11.2 0.6 75 80 3 0.8 21.6 120
7 VELAN 42 M 75524 12 11.8 0.2 65 85 3 1 25 120
8 KANNAN 50 M 53722 10.8 10.2 0.6 60 105 3 1 25 140
9 SUBASH 48 M 5275 11 10.4 0.6 75 65 2 0.76 15.2 120
10 VELLAITHAI 47 F 5373 11.4 11 0.4 70 60 2 0.68 16.4 120
11 NITHIN 19 M 24537 10.6 10 0.6 60 75 3 0.9 18.2 140
12 THANGARAJ 46 M 53753 10.8 10.6 0.2 65 70 3 0.88 20 140
13 THENDRAL 22 F 2753 11.8 11.6 0.2 60 50 2 0.86 15.8 140
14 SIVAPRIYA 46 F 74537 12 11.2 0.8 75 55 2 1 17.6 120
15 GANESH 33 M 24523 10.6 10.2 0.4 75 40 1 1 20.7 110
16 MALAR 28 F 52375 10.4 9.8 0.6 70 45 1 0.9 19.2 100
17 KAVITHA 27 F 75255 10.6 10.2 0.4 65 55 2 0.75 18.8 120
18 VIJAYAN 52 M 5752 11.4 11.2 0.2 60 50 2 0.74 17.9 120
19 VIMALA 46 F 2535 11.8 11.6 0.2 65 40 1 0.65 16.8 130
20 GANGA 22 F 5237 11 10.6 0.4 75 60 2 0.664 14.8 130
21 JASMINE 21 F 75752 12 11.4 0.6 75 60 2 0.7 19.2 125
22 PETER 15 M 52752 11.8 11.2 0.6 70 55 2 0.8 20 120
23 KUMAR 18 M 52755 10.6 10.2 0.4 70 50 2 0.72 21 110
24 VALLI 46 F 52752 10.4 11.6 0.8 70 45 1 0.68 18.6 100
25 RAMESH 19 M 45275 10.8 10.2 0.6 65 60 2 0.64 17.6 140
26 SURULI 40 F 24527 10.6 10.2 0.4 60 45 1 0.66 15.8 120
27 PANDI 42 M 24524 11.4 11.2 0.2 60 50 2 0.67 16.8 120
28 KALAIVANI 29 F 27522 11.2 10.8 0.4 60 50 2 0.8 17.2 130
29 DURAI 36 M 87852 11 10.2 0.8 70 55 2 0.82 18.6 120
30 MANGALA 34 F 53224 10.4 9.6 0.8 65 60 2 0.65 19.2 110
BISOPROLOL GROUP
S.No Name 0 min 10 mins 20 mins 30 mins 40 mins 50 mins 60 mins 70 mins
1 MURUGAN 88 90 88 83 88 83 99 88
2 SELVI 90 92 86 84 90 83 97
3 JEGAN 93 97 79 89 97 87 96
4 SURESH 89 87 86 97 86 86 83 87
5 ALAGAN 93 88 93 85 78 89 89 76
6 SAMI 79 84 92 87 88 85 86
7 THOTTICHI 88 92 80 80 78 89 97
8 KRISHNAN 80 80 87 89 95 93 89 89
9 RAJESWARI 93 83 85 86 95 91 80 99
10 LAKSHMI 97 88 70 79 88 89 90 93
11 KANDHI 80 89 79 94 90 85 92
12 VIRALI 86 93 89 96 97 80 98 97
13 MALACHAMY 79 94 95 98 87 88 86 93
14 SENTHIL 79 92 94 97 89 85 89 86
15 PAKIYAM 83 89 90 89 86 89 86 78
16 RAJESH 79 87 87 97 89 93 88
17 PALANI 80 79 86 90 97 94 89
18 PAECHI 83 80 93 93 86 91 99 93
19 SARAVANAN 89 81 97 88 87 88 97 94
20 MUTHU 92 92 89 79 80 79 95 90
21 VALLI 80 91 83 88 89 79 90 88
22 KUMARI 83 90 91 99 93 97 92
23 SELVI 92 93 87 97 94 88 94
24 PRAKASH 99 89 80 94 89 93 86 90
25 VINOTH 98 99 89 83 97 85 88 90
26 SELVARAJ 87 87 83 80 93 79 89 79
27 VENI 86 80 79 89 86 79 96 92
28 ANDAL 78 79 84 86 85 84 96
29 MEENAKSHI 85 89 85 77 80 88 92 91
30 PRABHU 80 83 82 89 99 89 83 88
CONTROL GROUP MAP
S.No Name 0 min 10 mins 20 mins 30 mins 40 mins 50 mins 60 mins 70 mins
1 SENTHIL 78 82 77 72 82 80 79 80
2 JOSEPH 69 73 74 71 81 83 74 78
3 PRIYA 77 78 72 81 79 79 78
4 SUGANTHI 68 77 73 82 69 70 72 77
5 PRIYA 72 68 66 65 65 77 74
6 BALA 88 70 64 68 69 75 68
7 VELAN 75 70 76 73 70 69 69 68
8 KANNAN 74 72 68 65 72 70 73 67
9 SUBASH 81 72 67 80 76 79 80
10 VELLAITHAI 68 78 88 80 80 81 73
11 NITHIN 69 74 76 72 83 72 71 72
12 THANGARAJ 72 69 74 78 83 79 66 68
13 THENDRAL 74 68 69 63 69 73 69 66
14 SIVAPRIYA 78 71 77 76 72 69 73 80
15 GANESH 73 78 70 74 75 80 81 64
16 MALAR 69 70 80 81 77 73 80
17 KAVITHA 78 80 82 79 78 75 69
18 VIJAYAN 72 81 84 80 72 77 81 77
19 VIMALA 72 82 86 80 71 68 77
20 GANGA 66 78 77 76 69 77 74
21 JASMINE 64 88 68 66 68 69 68 72
22 PETER 78 74 64 66 77 77 72 73
23 KUMAR 62 72 75 72 73 72 70
24 VALLI 61 69 76 71 78 80 79
25 RAMESH 88 68 72 70 72 68 70
26 SURULI 83 66 71 76 74 73 71 73
27 PANDI 79 77 69 69 70 70 68 71
28 KALAIVANI 70 78 82 70 76 72 68
29 DURAI 69 72 73 70 69 68 66
30 MANGALA 72 74 78 76 73 71 74
BISOPROLOL GROUP MAP
S.No Name 0 min 10 mins 20 mins 30 mins 40 mins 50 mins 60 mins 70 mins
1 MURUGAN 88 99 92 89 89 88 99 90
2 SELVI 89 90 98 96 87 89 98
3 JEGAN 86 93 99 97 89 97 95 87
4 SURESH 89 87 89 94 80 90 97 89
5 ALAGAN 84 89 94 102 99 99 93
6 SAMI 99 90 93 103 97 93 100
7 THOTTICHI 90 93 100 110 93 98 102 100
8 KRISHNAN 94 97 101 100 103 99 105 99
9 RAJESWARI 98 94 89 99 103 100 100 98
10 LAKSHMI 102 94 94 98 102 103 110
11 KANDHI 111 99 97 96 98 106 99 97
12 VIRALI 104 103 93 93 99 110 97 93
13 MALACHAMY 98 89 90 89 96 99 95 92
14 SENTHIL 90 90 92 88 89 97 88 89
15 PAKIYAM 99 93 99 97 80 93 79
16 RAJESH 98 98 92 96 87 89 89
17 PALANI 94 97 103 98 88 88 89 98
18 PAECHI 97 90 100 88 98 94 90 94
19 SARAVANAN 89 94 104 100 97 95 96 89
20 MUTHU 93 110 99 98 96 95 97 100
21 VALLI 96 110 96 97 94 89 94 101
22 KUMARI 96 103 98 98 89 99 94
23 SELVI 89 98 80 90 99 93 92
24 PRAKASH 85 99 89 90 90 90 91 90
25 VINOTH 79 94 85 98 93 94 99 95
26 SELVARAJ 100 96 97 90 93 94 90 88
27 VENI 103 97 96 93 89 88 95 90
28 ANDAL 90 89 100 93 86 93 93
29 MEENAKSHI 98 100 95 95 93 93 91 88
30 PRABHU 96 100 99 96 94 100 99 90
CONTROL GROUP HEART RATE
S.No Name 0 min 10 mins 20 mins 30 mins 40 mins 50 mins 60 mins 70 mins
1 SENTHIL 77 66 63 69 72 64 59 66
2 JOSEPH 72 68 66 64 73 72 60 63
3 PRIYA 66 65 67 65 71 68 63
4 SUGANTHI 68 66 68 67 66 66 68 70
5 PRIYA 67 67 65 68 62 64 67
6 BALA 69 66 67 64 78 68 63
7 VELAN 68 77 68 63 61 62 68 63
8 KANNAN 78 71 64 68 65 61 64 67
9 SUBASH 82 73 66 77 69 66 65
10 VELLAITHAI 73 75 67 72 72 63 61
11 NITHIN 75 72 68 73 73 77 77 72
12 THANGARAJ 73 78 64 78 65 63 72 66
13 THENDRAL 77 75 67 75 69 62 68 63
14 SIVAPRIYA 76 68 67 78 73 61 67 61
15 GANESH 69 69 65 68 78 67 63 64
16 MALAR 68 76 64 62 61 63 69 70
17 KAVITHA 65 62 67 62 60 62 64
18 VIJAYAN 64 68 77 68 70 71 65
19 VIMALA 67 73 73 69 63 66 77 71
20 GANGA 66 66 68 63 72 80 70
21 JASMINE 68 69 73 67 68 59 64 66
22 PETER 72 73 61 65 63 80 74 61
23 KUMAR 73 77 64 67 72 58 59
24 VALLI 72 72 77 63 70 63 63
25 RAMESH 66 77 62 68 70 63 66
26 SURULI 68 65 73 78 60 67 70 64
27 PANDI 69 62 68 77 63 71 70 64
28 KALAIVANI 64 61 68 66 64 72 74
29 DURAI 77 60 63 65 65 68 66
30 MANGALA 75 64 71 67 69 68 66
BISOPROLOL GROUP HEART RATE
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